{"gene":"ERG","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1987,"finding":"ERG (erg gene) encodes a protein with ~40% and ~70% homology to the 5' and 3' domains of v-ets oncogene, respectively, establishing it as a member of the ETS oncogene family with a distinct transcript size from Hu-ets1 and Hu-ets2.","method":"cDNA cloning, nucleotide sequence analysis, Northern blot","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct sequencing and biochemical characterization of the founding paper, independently replicated across the field","pmids":["3476934"],"is_preprint":false},{"year":1991,"finding":"ERG-1 and ERG-2 proteins (produced by alternative splicing and alternative initiation codons) bind DNA in a sequence-specific manner and transactivate reporter genes linked to ERG target sequences, establishing ERG as a sequence-specific transcriptional activator with partially overlapping but distinct DNA-binding specificity compared to other ETS members.","method":"Recombinant protein expression in E. coli, DNA-binding assays, transactivation reporter assays in transient transfection","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro biochemical reconstitution with purified recombinant protein plus functional transcription assay, foundational paper replicated by subsequent studies","pmids":["1766675"],"is_preprint":false},{"year":1994,"finding":"ERG gene on chromosome 21 is fused to the 5' end of EWS in Ewing's sarcoma, placing the ERG ETS DNA-binding domain adjacent to the EWS CTD-related region and generating an elevated EWS/ERG fusion transcript — the first reported structural alteration of ERG in human cancer.","method":"Cytogenetics, RT-PCR, transcript detection in cell line","journal":"Cancer genetics and cytogenetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — molecular characterization of the fusion in a cell line with RT-PCR validation, single lab","pmids":["8076344"],"is_preprint":false},{"year":2000,"finding":"The TLS-ERG leukemia fusion protein binds RNA polymerase II through its TLS N-terminal domain but, unlike wild-type TLS, cannot recruit serine-arginine (SR) splicing factors because the ERG portion replaces the TLS C-terminal SR-recruiting domain; as a result, TLS-ERG inhibits SR-mediated E1A pre-mRNA splicing and alters CD44 mRNA splicing in stable K562 cells.","method":"Co-immunoprecipitation, transient transfection splicing assay, stable expression in K562 cells, RT-PCR of CD44 splice variants, deletion analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (Co-IP, in-cell splicing assay, stable expression), mechanistic dissection with deletion mutants","pmids":["10779324"],"is_preprint":false},{"year":2001,"finding":"Among multiple ERG isoforms, Erg-3/p55(ERG) and p38(ERG)-like transcripts are selectively expressed in human endothelial cells (both microvascular and large vessel), suggesting isoform-specific roles in regulating endothelial-restricted genes.","method":"RT-PCR, Northern blotting, 5'-RACE on primary and established human endothelial cells","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct isoform characterization in freshly isolated and cultured ECs, multiple molecular methods, single lab","pmids":["11312105"],"is_preprint":false},{"year":2005,"finding":"TLS-ERG binds RNA polymerase II via its first 173 amino acids; in myeloid L-G cells TLS-ERG represses glycoprotein IX promoter activity, while in NIH 3T3 fibroblasts it alters E1A splicing but not GpIX transcription — demonstrating cell-type-specific mechanisms of transformation through different gene sets.","method":"Deletion mutant analysis, luciferase reporter assays, splicing reporter assay, stable retroviral expression, microarray gene expression profiling in two cell lines","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — systematic deletion analysis, dual cell-line model, multiple orthogonal functional readouts","pmids":["15988032"],"is_preprint":false},{"year":2007,"finding":"ERG and its splice variant C-1-1 (hERG3Δ81) are expressed in developing mouse limb joints and overexpression of hERG3Δ81 throughout the cartilaginous skeleton of transgenic mice inhibits chondrocyte maturation/hypertrophy (absent growth plates, loss of Indian hedgehog, collagen X, MMP-13) while maintaining articular markers, placing ERG downstream of GDF-5 in joint formation.","method":"In vivo transgenic mouse model (Col2a1-driven overexpression), GDF-5 bead implantation in explants, immunostaining and marker expression analysis","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo transgenic mouse with specific skeletal phenotype, GDF-5 induction experiment, replicated in two species (chick and mouse)","pmids":["17336282"],"is_preprint":false},{"year":2008,"finding":"ERG binds the VE-cadherin promoter (shown by ChIP) and transactivates it; inhibition of ERG in HUVECs reduces VE-cadherin expression, disrupts cell-cell contacts, and increases apoptosis; overexpression of VE-cadherin rescues ERG-knockdown-induced apoptosis; in vivo ERG siRNA reduces Matrigel plug vascularization with increased caspase-positive ECs.","method":"Antisense oligonucleotide knockdown, siRNA, chromatin immunoprecipitation (ChIP), transactivation assay, VE-cadherin-GFP overexpression rescue, in vivo Matrigel plug model, caspase staining","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP establishing direct promoter binding, in vitro functional rescue, in vivo vascularization model, multiple orthogonal methods","pmids":["18195090"],"is_preprint":false},{"year":2008,"finding":"TMPRSS2-ERG fusion product induces an invasion-associated transcriptional program in prostate epithelial cells and directly engages the plasminogen activation pathway to mediate cellular invasion; transgenic mice expressing ERG under androgen regulation develop prostatic intraepithelial neoplasia.","method":"Transgenic mouse model, stable overexpression in primary/immortalized prostate cells, ERG knockdown in VCaP cells, transcriptional profiling, invasion assays","journal":"Neoplasia","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo transgenic model plus in vitro gain/loss-of-function with defined invasion phenotype and pathway identification, replicated across multiple model systems","pmids":["18283340"],"is_preprint":false},{"year":2009,"finding":"Ectopic ERG expression in fetal hematopoietic progenitors promotes megakaryopoiesis and causes rapid-onset leukemia in mice; ERG cooperates strongly with the GATA1s mutant protein to immortalize megakaryocyte progenitors, and endogenous ERG is required for proliferation/maintenance of AMKL cell lines.","method":"Retroviral overexpression in fetal liver progenitors, in vivo mouse transplantation, shRNA knockdown of ERG in human AMKL lines, colony-forming assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo leukemia model plus human cell line loss-of-function, GATA1s cooperation established genetically, multiple labs have replicated the megakaryocytic oncogenic role","pmids":["19487285"],"is_preprint":false},{"year":2009,"finding":"ETS2 and ERG overexpression immortalize Gata1-knockdown and Gata1s-knockin (but not wild-type) murine fetal liver megakaryocyte progenitors in serial replating; immortalization is accompanied by activation of the JAK/STAT pathway.","method":"Retroviral overexpression in Gata1 mutant fetal liver progenitors, serial replating assay, flow cytometry (CD41/CD42), JAK/STAT signaling analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with Gata1 mutants, functional immortalization assay, pathway identification, independent confirmation of ERG-GATA1s cooperation","pmids":["19168790"],"is_preprint":false},{"year":2011,"finding":"ERG forced expression in adult bone marrow cells promotes T-cell and erythroid expansion and increases myeloid progenitor frequency; T cells develop T-ALL after acquiring Notch1 mutations; ERG targeted to B cells promotes precursor-B-cell growth; shRNA silencing of ERG attenuates growth of human leukemia lines of multiple lineages.","method":"Retroviral overexpression and shRNA knockdown in mouse BM transplantation models; B-cell targeted expression; human leukemia cell line knockdown","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo BM transplantation model plus human cell line KD, multi-lineage phenotypic characterization, independent of prior megakaryocyte work","pmids":["21321361"],"is_preprint":false},{"year":2011,"finding":"TMPRSS2-ERG directly binds the TFF3 promoter ETS sites (by ChIP and ChIP-seq), inhibiting TFF3 expression in hormone-naive cancer but not in castration-resistant prostate cancer; AR signaling modulates ERG-regulated TFF3 expression; TFF3 overexpression enhances ERG-mediated invasion in CRPC cells.","method":"ChIP-PCR and ChIP-seq in VCaP cells and tissue specimens, transcriptome profiling of 54 CRPC samples, invasion assays with TFF3 overexpression","journal":"Neoplasia","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct ChIP/ChIP-seq establishing promoter binding, validated in human tissue, functional invasion assay, multiple orthogonal methods","pmids":["21170267"],"is_preprint":false},{"year":2011,"finding":"ERG directly binds the PIM1 promoter (by ChIP) in prostate cells and upregulates PIM1 expression; all three ERG oncogenic fusions (TMPRSS2/ERG, EWS/ERG, FUS/ERG) upregulate PIM1 in NIH-3T3; tERG-induced PIM1 upregulation increases Cyclin B1 levels and aneuploidy after taxane treatment.","method":"Chromatin immunoprecipitation, stable expression of ERG fusions in NIH-3T3 and RWPE-1, siRNA knockdown, gene expression microarray, flow cytometry","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating direct promoter binding, consistent across three fusion types, single lab","pmids":["22140532"],"is_preprint":false},{"year":2013,"finding":"ERG-mediated regulation of SOX9 is indirect: ERG redirects AR to a cryptic AR-regulated enhancer in the SOX9 gene, thereby driving androgen-stimulated SOX9 expression; SOX9 depletion in VCaP cells impairs invasion and growth in vitro and in vivo, establishing SOX9 as a critical downstream effector of ERG.","method":"RNAi knockdown in VCaP cells, ChIP-seq to map ERG/AR binding at SOX9 enhancer, SOX9 shRNA knockdown, in vivo xenograft, correlation in 3 independent cohorts","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP-seq-defined mechanism, in vitro and in vivo functional validation, 3 independent clinical cohorts, multiple orthogonal methods","pmids":["23426182"],"is_preprint":false},{"year":2013,"finding":"ERG DNA binding is allosterically autoinhibited by flanking regions outside the ETS domain. Crystal structures of uninhibited, autoinhibited, and DNA-bound ERG were solved; NMR backbone dynamics show that uninhibited ERG exhibits millisecond-to-microsecond dynamics that are quenched in autoinhibited and DNA-bound states, revealing that autoinhibition is predominantly mediated by regulation of Ets-domain dynamics rather than large structural changes.","method":"X-ray crystallography (three crystal structures), NMR backbone dynamics measurements, functional DNA-binding assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures plus NMR dynamics plus functional assay, multiple orthogonal biophysical methods in single rigorous study","pmids":["23898196"],"is_preprint":false},{"year":2013,"finding":"ERG governs loss of DNA methylation at the TDRD1 promoter CpG island, leading to TDRD1 transcriptional activation in TMPRSS2:ERG-positive prostate cancer; this was demonstrated by ERG dosage manipulation (siRNA and forced expression) and MeDIP-seq/bisulfite sequencing showing inverse correlation between ERG and TDRD1 promoter methylation.","method":"siRNA knockdown and forced expression of ERG, MeDIP-Seq and bisulfite sequencing, DNMT inhibitor treatment, quantitative RT-PCR, clinical specimen analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MeDIP-seq and bisulfite sequencing with direct ERG dosage manipulation, single lab","pmids":["23555854"],"is_preprint":false},{"year":2013,"finding":"ERG is recruited to the ANXA2 promoter (shown by ChIP) and transcriptionally represses ANXA2; ERG knockdown enhances apical ANXA2 localization and promotes polarized epithelial phenotype; ERG overexpression disrupts ANXA2-mediated cell polarity and promotes EMT by inhibiting CDC42 and RHOA and activating cofilin.","method":"ChIP, siRNA knockdown, ERG overexpression, immunofluorescence of ANXA2 localization, RHOA/CDC42/cofilin activity assays, IHC in clinical specimens","journal":"Molecular cancer research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP-based direct promoter binding, gain/loss-of-function with defined signaling readouts, clinical specimen validation","pmids":["25344575"],"is_preprint":false},{"year":2014,"finding":"ERG overexpression in CRPC cells affects microtubule dynamics and inhibits effective drug-target engagement of docetaxel or cabazitaxel with tubulin, suggesting ERG functions outside the nucleus to confer taxane resistance.","method":"ERG overexpression in in vitro and in vivo CRPC models, microtubule dynamics assays, drug-target engagement assays, clinical cohort analysis (34 patients)","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic microtubule assay plus in vivo model, single lab, novel non-nuclear function proposed with functional data","pmids":["25420520"],"is_preprint":false},{"year":2014,"finding":"ERG cooperates with TGF-β signaling: ERG expression is induced by TGF-β in sclerotome cells; Erg and Smad3 co-immunoprecipitate, indicating direct protein-protein interaction; ERG overexpression inhibits hyaline cartilage differentiation (reduced Alcian blue, Sox9, c-Maf) and upregulates Sca1; TGF-β enhances ERG-mediated differentiation marker expression.","method":"Micromass culture, adenoviral ERG overexpression, co-immunoprecipitation (Erg/Smad3), TGF-β bead implantation in chick embryo, Alcian blue staining, qRT-PCR","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP establishing Erg/Smad3 interaction, in vitro and in vivo functional assays, single lab","pmids":["25139621"],"is_preprint":false},{"year":2015,"finding":"SPOP (Cullin 3-based E3 ubiquitin ligase adaptor) promotes ubiquitination and proteasomal degradation of ERG by recognizing a degron motif at the ERG N-terminus; truncated TMPRSS2-ERG fusion proteins lacking the N-terminal degron are resistant to SPOP-mediated degradation; prostate cancer-associated SPOP mutants are deficient in promoting ERG ubiquitination; CKI-mediated phosphorylation modulates the SPOP/ERG interaction; DNA damage drugs can restore SPOP/ΔERG interaction and degradation via CKI activation.","method":"Ubiquitination assay, co-immunoprecipitation, proteasome inhibitor treatment, SPOP mutant expression, CKI activation by DNA damage drugs, in vitro and in vivo experiments","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — biochemical ubiquitination assay, degron mapping, phosphorylation modulation, replicated in companion paper (PMID 26344096), two independent labs","pmids":["26344095","26344096"],"is_preprint":false},{"year":2015,"finding":"ERG activates the YAP1 transcriptional program: ERG binds chromatin regions co-occupied by TEAD/YAP1 and transactivates Hippo target genes; in human luminal prostate cancer cells, ERG binds the YAP1 promoter and is necessary for YAP1 expression; prostate-specific activation of ERG or YAP1 in mice induces similar transcriptional changes and age-related prostate tumors.","method":"ChIP-seq (ERG/TEAD/YAP1 binding), ERG and YAP1 promoter ChIP, mouse genetic models (prostate-specific ERG or YAP1 activation), transcriptional profiling","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP-seq genome-wide binding, in vivo genetic evidence of shared transcriptional program, direct promoter binding established","pmids":["26058078"],"is_preprint":false},{"year":2015,"finding":"ERG directly promotes YAP1 expression by binding to multiple sites within the human YAP1 gene promoter, cooperating with histone demethylase KDM4A (JMJD2A) which removes H3K9me3 at the YAP1 promoter; ERG and KDM4A physically interact (co-IP); YAP1 depletion phenocopies ERG or KDM4A depletion in VCaP cells.","method":"Co-immunoprecipitation (ERG-KDM4A), ChIP (H3K9me3 at YAP1 promoter), luciferase promoter assays with ERG-binding-site mutations, siRNA knockdown, growth assays","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP, ChIP, mutational promoter analysis, single lab","pmids":["27109047"],"is_preprint":false},{"year":2016,"finding":"ERG drives genome-wide retargeting of BAF (mammalian SWI/SNF) ATP-dependent chromatin remodeling complexes in a manner dependent on ERG binding to ETS DNA motifs; ERG requires intact BAF complexes for chromatin occupancy and BAF ATPase activity for target gene regulation; ERG interacts with BAF complexes (shown by binding interaction experiments); BAF complexes are required for ERG-mediated basal-to-luminal transition in prostate organoids.","method":"Co-immunoprecipitation/binding interaction experiments, ChIP-seq (ERG and BAF), BAF ATPase inhibition, prostate organoid model with BAF complex perturbation","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genome-wide ChIP-seq demonstrating ERG-dependent BAF retargeting, biochemical interaction, mechanistic dissection with organoid model, multiple orthogonal methods","pmids":["30078722"],"is_preprint":false},{"year":2016,"finding":"Combined knockdown of ERG and FLI1 in endothelial cells induces EndMT coupled with dynamic epigenetic changes; ERG (and FLI1) are critical transcriptional activators of EC-specific genes; microRNA-126, a target of ERG/FLI1, partially contributes to blocking EndMT; ERG and FLI1 expression is downregulated in ECs within tumors by soluble factors from the tumor microenvironment.","method":"siRNA knockdown (ERG, FLI1, combined), genome-wide ChIP-seq and ATAC-seq, EndMT phenotyping, miR-126 rescue experiments, conditioned medium experiments","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genome-wide chromatin and expression analysis plus functional EndMT assay, miR-126 rescue, multiple orthogonal methods","pmids":["30500808"],"is_preprint":false},{"year":2016,"finding":"The TMPRSS2-ERG truncated fusion protein (ERGΔ39/T1-E4) binds bromodomain-1 (BD1) of BRD4; this interaction is partially abrogated by BET inhibitors JQ1 and iBET762; ChIP-seq shows substantial overlap of ERG and BRD4 binding sites; an acetylation-mimicking ERG mutation augments the ERG-BRD4 interaction and enhances ERG-mediated invasion.","method":"Co-immunoprecipitation (ERG-BRD4), BET inhibitor treatment, ChIP-seq meta-analysis, acetylation-mimicking mutation, invasion assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and ChIP-seq with functional mutation, single lab, one method per key claim","pmids":["27223260"],"is_preprint":false},{"year":2016,"finding":"Deregulation of DUX4 in B-progenitor ALL initiates transcription of a novel ERG isoform (ERGalt) from a non-canonical first exon via DUX4 binding; ERGalt retains the DNA-binding and transactivation domains of ERG but acts as a dominant-negative inhibitor of wild-type ERG transcriptional activity and is transforming.","method":"RNA-seq, genomic rearrangement analysis, functional transactivation assays (dominant-negative), transformation assays, DUX4 binding site characterization","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — discovery of novel isoform with molecular mechanism defined (DUX4 binding, dominant-negative activity), functional transformation assays, large cohort study","pmids":["27776115"],"is_preprint":false},{"year":2017,"finding":"Peptides and derived peptidomimetics (ERG inhibitory peptides, EIPs) interact specifically with the DNA-binding domain of ERG; binding leads to proteolytic degradation of ERG protein; EIPs attenuate ERG-mediated transcription, chromatin recruitment, protein-protein interactions, cell invasion and proliferation, and tumor growth in vivo.","method":"Peptide binding assays, protease degradation assay, ERG ChIP after EIP treatment, transcriptional reporter assays, invasion/proliferation assays, xenograft tumor model","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — biochemical binding to specific domain, multiple functional readouts including in vivo, mechanistic degradation mechanism identified","pmids":["28344039"],"is_preprint":false},{"year":2017,"finding":"FOXO1 (but not FOXO3 or FOXO4) directly binds ERG and inhibits its transcriptional activity independently of FOXO1's own transcriptional activity; FOXO1 knockdown increases invasion of VCaP cells in an ERG-dependent manner; combined ERG overexpression and homozygous Foxo1 deletion in mouse prostate cooperates to produce high-grade PIN, while either alone does not.","method":"Co-immunoprecipitation (FOXO1-ERG), transcriptional reporter assay, siRNA knockdown, mouse genetic model (ERG transgene + Foxo1 deletion), cell invasion assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP establishing direct interaction, genetic epistasis in mouse model, biochemical activity assay, multiple orthogonal methods","pmids":["28986382"],"is_preprint":false},{"year":2019,"finding":"ERG directly and specifically regulates expression of the α1 and β1 subunits of soluble guanylyl cyclase (sGC) in prostate cancer cells; ERG-driven sGC expression increases cGMP synthesis and PKG activity, promoting cell proliferation; sGC inhibitor treatment represses TMPRSS2-ERG-positive tumor growth in xenograft models and synergizes with enzalutamide.","method":"ERG knockdown/overexpression in PCa cells, ChIP (ERG at sGC subunit loci), cGMP measurement, PKG activity assay, xenograft tumor model, pharmacological inhibition","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP-defined direct regulation, biochemical pathway readout (cGMP/PKG), in vivo xenograft, multiple orthogonal methods","pmids":["30718921"],"is_preprint":false},{"year":2020,"finding":"DNA damage induces proteasomal degradation of ERG and TMPRSS2-ERG oncoprotein through dual phosphorylation at threonine-187 (by GSK3β) and tyrosine-190 (by WEE1); this dual phosphorylation triggers recognition and degradation by the E3 ubiquitin ligase FBW7 independent of a canonical degron; DNA-damage-induced TMPRSS2-ERG degradation is abolished by PTEN deletion or GSK3β inactivation.","method":"In vitro phosphorylation assays, ubiquitination assays, mutagenesis (T187 and Y190), FBW7 Co-IP and degradation assays, GSK3β/WEE1 inhibition, PTEN deletion models, xenograft chemotherapy experiments","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assays, site-directed mutagenesis, biochemical ubiquitination reconstitution, in vivo validation, mechanistic dissection of novel PTM-driven degradation pathway","pmids":["32871104"],"is_preprint":false},{"year":2020,"finding":"ERG initiates a transcriptional network in early B lymphoid differentiation, directly promoting expression of B-cell lineage-defining genes Ebf1 and Pax5, which in turn regulate key genes for V(D)J recombination and B-cell receptor formation; ERG deficiency in B-cell development is rescued by a productively rearranged immunoglobulin gene, placing ERG as an essential stage-specific regulator upstream of V(D)J recombination.","method":"Erg conditional knockout, transcriptional profiling, ChIP-seq, Ig gene rescue complementation experiment, flow cytometric characterization of B-cell progenitor stages","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic rescue experiment establishing epistasis, ChIP-seq identifying direct targets, conditional KO with precise developmental phenotype","pmids":["32541654"],"is_preprint":false},{"year":2020,"finding":"ERG orchestrates 3D chromatin interactions in prostate cancer to enforce luminal cell identity: ERG binds and inhibits the enhancer activity and chromatin looping of a Trp63 distal enhancer, silencing Trp63 expression and suppressing basal lineage differentiation; specific deletion of the ERG-bound distal enhancer element abolishes ERG-mediated inhibition of basal differentiation.","method":"Integration of transcription factor analysis across 806 human PCa transcriptomes, 3D chromatin architecture analysis (Hi-C/chromatin conformation), ChIP-seq, CRISPR enhancer deletion, ERG/AR conditional KO in organoids","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genome-wide chromatin architecture, CRISPR enhancer deletion establishing causality, conditional KO epistasis, multiple orthogonal methods","pmids":["32701507"],"is_preprint":false},{"year":2020,"finding":"In established prostate cancer organoids, ERG deletion does not drastically alter AR binding, H3K27ac enhancer, or open chromatin profiles at ERG-reprogrammed sites, but does cause loss of critical AR coregulators (NCOA3) and RNA polymerase II from AR-bound sites, revealing that ERG maintains AR signaling by sustaining coregulator complexes rather than by controlling AR binding.","method":"Murine prostate organoids (Pten KO + ERG OE), ERG deletion in established organoids, ChIP-seq (AR, H3K27ac), ATAC-seq, proteomic analysis of DNA-bound AR complexes","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — proteomics of AR complexes, ChIP-seq and ATAC-seq genome-wide, organoid genetic model, multiple orthogonal methods","pmids":["32934023"],"is_preprint":false},{"year":2021,"finding":"EZH2 methylates ERG at lysine K362 within the internal autoinhibitory domain; K362 methylation modifies intradomain interactions, favors DNA binding, and enhances ERG transcriptional activity; in PTEN-null prostate cancer, AKT activation leads to EZH2 phosphorylation at serine 21, promoting ERG methylation; ERG and EZH2 physically interact and co-occupy genomic sites forming trans-activating complexes.","method":"In vitro methylation assay, site-directed mutagenesis (K362), Co-IP (ERG-EZH2), ChIP-seq, genetically engineered mouse model (ERG/PTEN), AKT/EZH2 signaling dissection","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro methylation reconstitution with mutagenesis, structural domain mechanistic dissection, in vivo mouse model, ChIP-seq co-occupancy, multiple orthogonal methods","pmids":["34230470"],"is_preprint":false},{"year":2021,"finding":"ERG upregulates wild-type SPOP to dampen AR signaling and sustains its own activity through SPOP-mediated degradation of the bromodomain histone reader ZMYND11; conversely, SPOP-mutant tumors stabilize ZMYND11 which represses ERG function, creating a synthetic-sick interaction between ERG and SPOP mutation; ERG promotes sensitivity to high-dose androgen therapy and pharmacological SPOP inhibition.","method":"ERG/SPOP gain and loss of function, ZMYND11 protein stability assays, AR signaling readouts, pharmacological inhibition, clinical cohort analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic dissection of ERG-SPOP-ZMYND11-AR axis, pharmacological and genetic perturbation, clinical validation, multiple orthogonal methods","pmids":["33531470"],"is_preprint":false},{"year":2021,"finding":"ERG knockdown in endothelial cells (HUVECs) promotes secretion of endothelin-1 (ET-1), which in a paracrine manner accelerates proliferation, phenotypic transition, and collagen synthesis of cardiac fibroblasts; suppressing ET-1 (neutralizing antibody or receptor blocker) abolishes ERG-knockdown-mediated pro-fibrotic effects; endothelial ERG overexpression prevents pressure-overload-induced cardiac fibrosis in vivo.","method":"siRNA knockdown of ERG in HUVECs, ET-1 ELISA, cardiac fibroblast co-culture/conditioned medium, ET-1 neutralizing antibody/receptor blocker, RGD-peptide nanoparticle siRNA delivery in vivo, pressure-overload mouse model with ERG overexpression","journal":"Cell biology and toxicology","confidence":"High","confidence_rationale":"Tier 2 / Strong — paracrine mechanism identified with ET-1 rescue, in vivo mouse model, pharmacological and genetic interventions, multiple orthogonal methods","pmids":["33469864"],"is_preprint":false},{"year":2022,"finding":"EVI1 oncogene directly transcriptionally activates ERG by occupying a conserved intragenic enhancer region; ERG is a direct transcriptional target of EVI1 and is selectively required in EVI1-driven AML; ERG suppression induces terminal differentiation of EVI1-driven AML cells; ectopic ERG expression abrogates EVI1 dependence, placing ERG downstream of EVI1 as the major oncogenic effector.","method":"EVI1 withdrawal experiments, genome-wide CRISPR screens for dependencies, ChIP-seq (EVI1 at ERG enhancer), ERG shRNA knockdown, ERG ectopic expression rescue, differentiation assays in human and murine AML models","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP-seq direct enhancer binding, CRISPR genetic dependency, genetic rescue epistasis, validated in human and murine models","pmids":["36095844"],"is_preprint":false},{"year":2022,"finding":"Loss of endothelial ERG in young mice impairs lung fibrosis resolution; ERG dysregulation in aged lungs is associated with reduced chromatin accessibility at ERG target loci and maladaptive transcriptional responses to injury; ERG deficiency enhances paracrine fibroblast activation in vitro; scRNA-seq of ERG-deficient mouse lungs shows transcriptional and fibrogenic abnormalities resembling aging, including reduced general capillary (gCap) ECs.","method":"Conditional endothelial ERG KO, bleomycin fibrosis model, ATAC-seq (epigenetic chromatin accessibility), scRNA-seq, in vitro paracrine fibroblast activation assay, young vs. aged mouse comparison","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — conditional KO with in vivo fibrosis model, ATAC-seq, scRNA-seq, in vitro mechanistic assay, multiple orthogonal methods","pmids":["35879310"],"is_preprint":false},{"year":2022,"finding":"HNF1B interacts with TMPRSS2-ERG to co-occupy large genomic regions enriched for PCa risk alleles; the HNF1B eQTL signal is ERG fusion-status dependent, indicating that ERG mediates the transcriptional effects of the 17q12/HNF1B risk locus; HNF1B co-opts ERG fusion to mediate the biological effects of the 17p13.3 PCa risk locus.","method":"Co-expression analysis, eQTL analysis stratified by ERG status, ChIP-seq co-occupancy analysis, functional pathway analysis","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq co-occupancy and eQTL conditional on ERG status, single study, predominantly genomic/computational with functional validation","pmids":["36443337"],"is_preprint":false}],"current_model":"ERG is an ETS-family transcription factor that binds DNA sequence-specifically (with autoinhibition mediated by flanking domains regulating Ets-domain dynamics), transactivates or represses target genes (including VE-cadherin, SOX9, YAP1, sGC subunits, TFF3, PIM1, ANXA2, FZD8, TDRD1, and Trp63 enhancer), physically interacts with AR, BAF chromatin remodeling complexes, BRD4, EZH2 (which methylates ERG at K362 to enhance DNA binding), FOXO1 (which inhibits ERG), Smad3, and RNA polymerase II; its protein stability is regulated by SPOP/CRL3-mediated ubiquitin-proteasomal degradation (targeting an N-terminal degron, modulated by CKI and by GSK3β/WEE1-dependent dual phosphorylation that recruits FBW7); in the vasculature ERG is essential for endothelial survival, angiogenesis, and homeostasis, partly through direct transactivation of VE-cadherin and suppression of ET-1 secretion; in hematopoiesis ERG drives megakaryopoiesis, maintains hematopoietic stem cells, and is the key downstream effector of EVI1-driven AML; in prostate cancer the TMPRSS2-ERG fusion redirects AR to cryptic enhancers (e.g., SOX9), retargets BAF complexes genome-wide, maintains coregulator (NCOA3) recruitment to AR-bound sites, orchestrates chromatin looping to suppress basal lineage differentiation, and is regulated by EZH2 methylation and SPOP/FBW7 degradation pathways; in the TLS-ERG leukemia fusion, the ERG portion displaces TLS C-terminal SR splicing-factor recruitment, causing aberrant RNA splicing and cell-type-specific transcriptional reprogramming."},"narrative":{"mechanistic_narrative":"ERG is an ETS-family sequence-specific transcription factor that orchestrates lineage-defining transcriptional programs in vascular endothelium, hematopoiesis, and skeletal development, and is co-opted as a dominant oncogenic driver when structurally rearranged [PMID:3476934, PMID:1766675, PMID:18283340]. Its DNA-binding ETS domain is allosterically autoinhibited by flanking regions that quench Ets-domain conformational dynamics, a regulatory switch relieved by EZH2-mediated methylation of K362 within the internal autoinhibitory domain to favor DNA binding and transactivation [PMID:23898196, PMID:34230470]. In the vasculature ERG directly transactivates VE-cadherin to maintain endothelial cell-cell junctions and survival, supports angiogenesis, and represses endothelin-1 secretion, thereby restraining paracrine fibroblast activation and cardiac/lung fibrosis; combined loss with FLI1 drives endothelial-to-mesenchymal transition [PMID:18195090, PMID:33469864, PMID:30500808, PMID:35879310]. In hematopoiesis ERG drives megakaryopoiesis, cooperates with the GATA1s mutant to immortalize progenitors, supports B-lymphoid differentiation upstream of Ebf1/Pax5 and V(D)J recombination, and is the principal transcriptional effector of EVI1-driven AML [PMID:19487285, PMID:19168790, PMID:32541654, PMID:36095844]. When fused (TMPRSS2-ERG, EWS-ERG, FUS/TLS-ERG), ERG reprograms transcription: it retargets BAF/SWI-SNF chromatin remodeling complexes genome-wide, redirects AR to cryptic enhancers and sustains AR coregulator (NCOA3) and Pol II occupancy, orchestrates 3D chromatin looping to silence the Trp63 enhancer and suppress basal differentiation, and directly activates or represses targets including SOX9, YAP1 (with KDM4A), the sGC α1/β1 subunits, TFF3, PIM1, ANXA2, and TDRD1 to promote invasion and proliferation [PMID:30078722, PMID:32934023, PMID:32701507, PMID:23426182, PMID:26058078, PMID:30718921]. The TLS-ERG fusion instead acts through RNA Pol II binding while failing to recruit SR splicing factors, causing aberrant, cell-type-specific RNA splicing [PMID:10779324, PMID:15988032]. ERG protein abundance is tightly controlled by ubiquitin-proteasomal degradation through the SPOP/CRL3 adaptor recognizing an N-terminal degron and through GSK3β/WEE1 dual phosphorylation (T187/Y190) that recruits FBW7, pathways exploited by truncated fusions that escape degron-dependent turnover [PMID:26344095, PMID:26344096, PMID:32871104].","teleology":[{"year":1987,"claim":"Establishing the molecular identity of ERG answered whether it was a distinct gene, defining it as a member of the ETS oncogene family separate from ets1/ets2.","evidence":"cDNA cloning, sequencing, and Northern blot","pmids":["3476934"],"confidence":"High","gaps":["Did not define DNA-binding specificity or transcriptional function","No cellular role assigned"]},{"year":1991,"claim":"Showing ERG isoforms bind DNA sequence-specifically and transactivate reporters established ERG as a bona fide transcription factor rather than merely an ETS-homologous ORF.","evidence":"Recombinant protein DNA-binding and transactivation reporter assays","pmids":["1766675"],"confidence":"High","gaps":["Physiological target genes unknown","Tissue context undefined"]},{"year":1994,"claim":"Identifying EWS-ERG fusion in Ewing's sarcoma revealed that ERG's ETS domain becomes oncogenic through structural fusion, the first cancer alteration of ERG.","evidence":"Cytogenetics and RT-PCR in a cell line","pmids":["8076344"],"confidence":"Medium","gaps":["Single cell line, no mechanistic dissection of fusion activity","Target genes of fusion not defined"]},{"year":2000,"claim":"Dissecting the TLS-ERG fusion answered how it transforms, revealing that the ERG portion displaces TLS SR splicing-factor recruitment to cause aberrant splicing while retaining Pol II binding.","evidence":"Co-IP, in-cell splicing assays, deletion analysis in K562 cells","pmids":["10779324"],"confidence":"High","gaps":["In vivo leukemogenesis not shown","Full set of mis-spliced transcripts unknown"]},{"year":2005,"claim":"Comparing TLS-ERG effects across cell lines established that its transcriptional/splicing consequences are cell-type-specific, mapping Pol II binding to the N-terminal 173 residues.","evidence":"Deletion mutants, reporter and splicing assays, microarrays in two cell lines","pmids":["15988032"],"confidence":"High","gaps":["Determinants of cell-type specificity not identified","Primary patient relevance untested"]},{"year":2008,"claim":"Identifying VE-cadherin as a direct ERG target answered how ERG maintains the endothelium, linking ERG to junctional integrity, survival, and angiogenesis.","evidence":"ChIP, knockdown/rescue, in vivo Matrigel plug, caspase staining","pmids":["18195090"],"confidence":"High","gaps":["Full endothelial target network not mapped","Upstream regulators of ERG in EC unknown"]},{"year":2008,"claim":"Linking TMPRSS2-ERG to an invasion program and PIN in transgenic mice established ERG fusion as a driver of prostate oncogenesis via the plasminogen activation pathway.","evidence":"Transgenic mice, gain/loss-of-function in prostate cells, invasion assays","pmids":["18283340"],"confidence":"High","gaps":["Direct chromatin targets not yet defined","Cooperating lesions for full transformation unclear"]},{"year":2011,"claim":"Multiple studies established ERG as a broad hematopoietic oncogene, driving megakaryopoiesis, cooperating with GATA1s, and supporting multi-lineage leukemias.","evidence":"Retroviral overexpression/shRNA in mouse BM transplants and human leukemia lines, serial replating, JAK/STAT analysis","pmids":["19487285","19168790","21321361"],"confidence":"High","gaps":["Direct transcriptional targets in each lineage incompletely defined","Mechanism of GATA1s cooperation at chromatin unresolved"]},{"year":2013,"claim":"Solving ERG crystal structures with NMR dynamics answered how DNA binding is regulated, showing autoinhibition operates by quenching Ets-domain dynamics rather than gross conformational change.","evidence":"Three X-ray structures, NMR backbone dynamics, DNA-binding assays","pmids":["23898196"],"confidence":"High","gaps":["How post-translational modifications alter these dynamics not addressed here","Partner-protein influence on autoinhibition unknown"]},{"year":2013,"claim":"Mapping ERG-regulated targets in prostate cancer (SOX9, TFF3, PIM1, TDRD1, ANXA2) revealed both direct ETS-site binding and AR-redirection, establishing the effector genes for invasion and EMT.","evidence":"ChIP/ChIP-seq, MeDIP-seq, knockdown/overexpression, xenografts, clinical cohorts","pmids":["23426182","21170267","22140532","23555854","25344575"],"confidence":"High","gaps":["Relative contribution of each target to tumorigenesis unranked","Direct vs. AR-mediated mechanism varies by target"]},{"year":2014,"claim":"Identifying a non-nuclear ERG effect on microtubule dynamics proposed a mechanism for taxane resistance distinct from its transcriptional role.","evidence":"Overexpression, microtubule and drug-target engagement assays, clinical cohort","pmids":["25420520"],"confidence":"Medium","gaps":["Direct ERG-tubulin interaction not biochemically defined","Single lab, mechanism of cytoplasmic localization unclear"]},{"year":2014,"claim":"Demonstrating ERG-Smad3 interaction and TGF-β induction of ERG connected ERG to TGF-β signaling in skeletal differentiation.","evidence":"Micromass culture, Co-IP, TGF-β bead implantation in chick, marker analysis","pmids":["25139621"],"confidence":"Medium","gaps":["Co-IP not reciprocally validated for endogenous proteins","Direct target genes of ERG-Smad3 complex undefined"]},{"year":2015,"claim":"Identifying SPOP/CRL3 as the E3 ligase recognizing an N-terminal ERG degron answered how ERG protein is degraded and why truncated fusions escape turnover.","evidence":"Ubiquitination assays, degron mapping, SPOP-mutant and CKI/DNA-damage modulation, in vivo","pmids":["26344095","26344096"],"confidence":"High","gaps":["Interplay with other degradation pathways not yet integrated","CKI site on ERG not precisely mapped here"]},{"year":2015,"claim":"Establishing the ERG-YAP1/Hippo axis (with KDM4A cooperation) revealed a transcriptional program shared with YAP1 that drives prostate tumorigenesis.","evidence":"ChIP-seq, promoter ChIP/luciferase, Co-IP, mouse genetic models","pmids":["26058078","27109047"],"confidence":"High","gaps":["Whether YAP1 fully accounts for ERG tumor phenotype unresolved","KDM4A-ERG interaction from single lab"]},{"year":2016,"claim":"Defining ERG's recruitment of BAF remodelers and interaction with BRD4 answered how fusion ERG reorganizes chromatin to reprogram lineage identity.","evidence":"Co-IP/binding, ChIP-seq, BAF ATPase inhibition, organoids, BET inhibitor and acetylation-mimic experiments","pmids":["30078722","27223260"],"confidence":"High","gaps":["Stoichiometry and direct interface of ERG-BAF binding undefined","BRD4 interaction characterized in single lab"]},{"year":2016,"claim":"Discovering EndMT control by ERG/FLI1 and ERGalt dominant-negative isoform expanded ERG's roles to endothelial identity maintenance and a novel B-ALL transforming mechanism.","evidence":"siRNA knockdown, ChIP-seq/ATAC-seq, miR-126 rescue, RNA-seq, transactivation/transformation assays","pmids":["30500808","27776115"],"confidence":"High","gaps":["Generality of ERGalt across B-ALL subtypes incompletely defined","Tumor-microenvironment factors downregulating ERG unidentified"]},{"year":2017,"claim":"ERG inhibitory peptides binding the DNA-binding domain established druggability and confirmed that disrupting ERG-DNA/protein interactions degrades ERG and blocks tumor growth.","evidence":"Peptide binding, protease degradation assay, ChIP, reporter and invasion assays, xenografts","pmids":["28344039"],"confidence":"High","gaps":["Degradation mechanism downstream of peptide binding not fully detailed","Clinical translation untested"]},{"year":2017,"claim":"Identifying FOXO1 as a direct ERG-binding inhibitor revealed an endogenous brake on ERG transcriptional activity that cooperates genetically in PIN.","evidence":"Co-IP, reporter assays, knockdown, mouse ERG transgene + Foxo1 deletion, invasion","pmids":["28986382"],"confidence":"High","gaps":["Structural basis of FOXO1-ERG inhibition undefined","Whether FOXO1 affects ERG at all target loci unknown"]},{"year":2019,"claim":"Linking ERG to direct activation of sGC α1/β1 subunits revealed a cGMP/PKG proliferative pathway and a druggable vulnerability synergizing with enzalutamide.","evidence":"ChIP, knockdown/overexpression, cGMP/PKG assays, xenografts, pharmacological inhibition","pmids":["30718921"],"confidence":"High","gaps":["Whether sGC axis operates in non-prostate ERG contexts untested","Upstream signals converging on this pathway unclear"]},{"year":2020,"claim":"Three studies clarified how fusion ERG maintains AR signaling and lineage identity: it sustains AR coregulators/Pol II rather than AR binding, and enforces luminal identity by silencing a Trp63 enhancer through 3D looping; ERG also governs B-lineage transcription.","evidence":"Organoid ERG deletion, AR/H3K27ac ChIP-seq, ATAC-seq, proteomics, Hi-C, CRISPR enhancer deletion, conditional KO, Ig rescue","pmids":["32701507","32934023","32541654"],"confidence":"High","gaps":["Mechanism by which ERG retains NCOA3/Pol II at AR sites undefined","Generalizability of looping mechanism to other ERG targets unknown"]},{"year":2020,"claim":"Defining GSK3β/WEE1 dual phosphorylation (T187/Y190) recruiting FBW7 revealed a degron-independent, DNA-damage-inducible route to ERG degradation gated by PTEN status.","evidence":"Kinase and ubiquitination assays, mutagenesis, FBW7 Co-IP, PTEN deletion, xenograft chemotherapy","pmids":["32871104"],"confidence":"High","gaps":["Crosstalk with SPOP/CKI degron pathway not fully integrated","Whether this operates in non-prostate ERG tumors untested"]},{"year":2021,"claim":"EZH2 methylation of ERG-K362 and the ERG-SPOP-ZMYND11 feedback loop answered how ERG activity and stability are reciprocally tuned, linking PTEN/AKT signaling and SPOP-mutation status to ERG function.","evidence":"In vitro methylation, mutagenesis, Co-IP, ChIP-seq, ERG/PTEN mouse model, ZMYND11 stability and clinical analyses","pmids":["34230470","33531470"],"confidence":"High","gaps":["Quantitative impact of K362 methylation on genome-wide binding incompletely mapped","Therapeutic exploitation of SPOP-ERG synthetic-sick interaction unproven clinically"]},{"year":2022,"claim":"Establishing ERG as the direct EVI1 transcriptional effector and the HNF1B partnership clarified ERG's place in AML dependency and prostate cancer risk-locus biology.","evidence":"EVI1 withdrawal, CRISPR screens, ChIP-seq, shRNA/ectopic rescue, eQTL stratified by ERG status","pmids":["36095844","36443337"],"confidence":"High","gaps":["HNF1B finding predominantly genomic, single study","Direct ERG-HNF1B physical interaction not biochemically confirmed"]},{"year":2022,"claim":"Endothelial ERG was shown to govern fibrosis resolution and aging-associated chromatin accessibility, extending its homeostatic role to tissue repair.","evidence":"Conditional endothelial KO, bleomycin model, ATAC-seq, scRNA-seq, paracrine assays","pmids":["35879310"],"confidence":"High","gaps":["Direct ERG targets driving fibrosis resolution not pinpointed","Mechanism of age-related ERG dysregulation unknown"]},{"year":null,"claim":"How the multiple ERG-regulatory layers — autoinhibition, K362 methylation, dual degron/phosphodegron degradation pathways, and partner complexes — are integrated to set context-specific ERG output across endothelium, hematopoiesis, and tumors remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No unified model coordinating ERG PTMs, stability, and chromatin partners","Determinants of cell-type-specific target selection undefined","Translation of ERG-targeting strategies to clinic untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,7,8,14,21,29,31,37]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[1,15,27]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[3,5]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,7,23,32]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,7,8,14,21,29]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[23,24,32,34]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,8,26,37]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[20,30,35]}],"complexes":["BAF (mammalian SWI/SNF)"],"partners":["AR","BRD4","EZH2","FOXO1","SMAD3","KDM4A","SPOP","FBW7"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P11308","full_name":"Transcriptional regulator ERG","aliases":["Transforming protein ERG"],"length_aa":479,"mass_kda":53.8,"function":"Transcriptional regulator. May participate in transcriptional regulation through the recruitment of SETDB1 histone methyltransferase and subsequent modification of local chromatin structure","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P11308/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ERG","classification":"Not Classified","n_dependent_lines":11,"n_total_lines":1208,"dependency_fraction":0.009105960264900662},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ERG","total_profiled":1310},"omim":[{"mim_id":"621567","title":"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ibb; CDG1BB","url":"https://www.omim.org/entry/621567"},{"mim_id":"621558","title":"RETINAL DYSTROPHY, ZEITZ-HAN TYPE; RDZH","url":"https://www.omim.org/entry/621558"},{"mim_id":"621548","title":"RETINITIS PIGMENTOSA 101; RP101","url":"https://www.omim.org/entry/621548"},{"mim_id":"621543","title":"UBIQUITIN-ASSOCIATED PROTEIN 1-LIKE PROTEIN; UBAP1L","url":"https://www.omim.org/entry/621543"},{"mim_id":"621481","title":"MITOCHONDRIAL DNA DEPLETION SYNDROME 14A (ENCEPHALOMYOPATHIC TYPE); MTDPS14A","url":"https://www.omim.org/entry/621481"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":38.4}],"url":"https://www.proteinatlas.org/search/ERG"},"hgnc":{"alias_symbol":["erg-3","p55"],"prev_symbol":[]},"alphafold":{"accession":"P11308","domains":[{"cath_id":"1.10.150.50","chopping":"130-204","consensus_level":"high","plddt":83.7493,"start":130,"end":204},{"cath_id":"1.10.10.10","chopping":"291-398","consensus_level":"high","plddt":87.235,"start":291,"end":398}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P11308","model_url":"https://alphafold.ebi.ac.uk/files/AF-P11308-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P11308-F1-predicted_aligned_error_v6.png","plddt_mean":59.34},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ERG","jax_strain_url":"https://www.jax.org/strain/search?query=ERG"},"sequence":{"accession":"P11308","fasta_url":"https://rest.uniprot.org/uniprotkb/P11308.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P11308/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P11308"}},"corpus_meta":[{"pmid":"18283340","id":"PMC_18283340","title":"Role of the TMPRSS2-ERG gene fusion in prostate cancer.","date":"2008","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18283340","citation_count":565,"is_preprint":false},{"pmid":"22736790","id":"PMC_22736790","title":"The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.","date":"2012","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22736790","citation_count":271,"is_preprint":false},{"pmid":"27776115","id":"PMC_27776115","title":"Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.","date":"2016","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27776115","citation_count":251,"is_preprint":false},{"pmid":"23426182","id":"PMC_23426182","title":"ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23426182","citation_count":230,"is_preprint":false},{"pmid":"18195090","id":"PMC_18195090","title":"Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18195090","citation_count":227,"is_preprint":false},{"pmid":"25915839","id":"PMC_25915839","title":"The oncogene ERG: a key factor in prostate cancer.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25915839","citation_count":211,"is_preprint":false},{"pmid":"17032499","id":"PMC_17032499","title":"TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions.","date":"2006","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/17032499","citation_count":197,"is_preprint":false},{"pmid":"3476934","id":"PMC_3476934","title":"The erg gene: a human gene related to the ets oncogene.","date":"1987","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3476934","citation_count":188,"is_preprint":false},{"pmid":"26344095","id":"PMC_26344095","title":"SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26344095","citation_count":181,"is_preprint":false},{"pmid":"21336263","id":"PMC_21336263","title":"ERG gene rearrangements are common in prostatic small cell carcinomas.","date":"2011","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/21336263","citation_count":169,"is_preprint":false},{"pmid":"26615022","id":"PMC_26615022","title":"A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.","date":"2015","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/26615022","citation_count":157,"is_preprint":false},{"pmid":"26344096","id":"PMC_26344096","title":"Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26344096","citation_count":136,"is_preprint":false},{"pmid":"20118910","id":"PMC_20118910","title":"Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.","date":"2010","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/20118910","citation_count":130,"is_preprint":false},{"pmid":"21677539","id":"PMC_21677539","title":"Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.","date":"2011","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21677539","citation_count":130,"is_preprint":false},{"pmid":"27208692","id":"PMC_27208692","title":"Regulation of endothelial homeostasis, vascular development and angiogenesis by the transcription factor ERG.","date":"2016","source":"Vascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27208692","citation_count":120,"is_preprint":false},{"pmid":"26690869","id":"PMC_26690869","title":"Ewing sarcoma with ERG gene rearrangements: A molecular study focusing on the prevalence of FUS-ERG and common pitfalls in detecting EWSR1-ERG fusions by FISH.","date":"2015","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26690869","citation_count":114,"is_preprint":false},{"pmid":"10779324","id":"PMC_10779324","title":"TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10779324","citation_count":113,"is_preprint":false},{"pmid":"26058078","id":"PMC_26058078","title":"ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.","date":"2015","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/26058078","citation_count":113,"is_preprint":false},{"pmid":"34397171","id":"PMC_34397171","title":"Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG.","date":"2021","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/34397171","citation_count":106,"is_preprint":false},{"pmid":"19487285","id":"PMC_19487285","title":"ERG is a megakaryocytic oncogene.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19487285","citation_count":102,"is_preprint":false},{"pmid":"24505269","id":"PMC_24505269","title":"TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24505269","citation_count":100,"is_preprint":false},{"pmid":"16140924","id":"PMC_16140924","title":"The proto-oncogene ERG in megakaryoblastic leukemias.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16140924","citation_count":98,"is_preprint":false},{"pmid":"22766791","id":"PMC_22766791","title":"Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma.","date":"2012","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/22766791","citation_count":97,"is_preprint":false},{"pmid":"25420520","id":"PMC_25420520","title":"ERG induces taxane resistance in castration-resistant prostate cancer.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25420520","citation_count":97,"is_preprint":false},{"pmid":"19168790","id":"PMC_19168790","title":"ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19168790","citation_count":97,"is_preprint":false},{"pmid":"8258524","id":"PMC_8258524","title":"The effects of dystrophin gene mutations on the ERG in mice and humans.","date":"1993","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/8258524","citation_count":93,"is_preprint":false},{"pmid":"11142742","id":"PMC_11142742","title":"Multifocal ERG and VEP responses and visual fields: comparing disease-related changes.","date":"2000","source":"Documenta ophthalmologica. Advances in ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/11142742","citation_count":91,"is_preprint":false},{"pmid":"30078722","id":"PMC_30078722","title":"Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.","date":"2018","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/30078722","citation_count":89,"is_preprint":false},{"pmid":"17336282","id":"PMC_17336282","title":"Transcription factor ERG and joint and articular cartilage formation during mouse limb and spine skeletogenesis.","date":"2007","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/17336282","citation_count":87,"is_preprint":false},{"pmid":"28849022","id":"PMC_28849022","title":"Significance of the TMPRSS2:ERG gene fusion in prostate cancer.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28849022","citation_count":85,"is_preprint":false},{"pmid":"21559405","id":"PMC_21559405","title":"YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21559405","citation_count":85,"is_preprint":false},{"pmid":"23774169","id":"PMC_23774169","title":"ERG expression in epithelioid sarcoma: a diagnostic pitfall.","date":"2013","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23774169","citation_count":82,"is_preprint":false},{"pmid":"33469864","id":"PMC_33469864","title":"Endothelial ERG alleviates cardiac fibrosis via blocking endothelin-1-dependent paracrine mechanism.","date":"2021","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/33469864","citation_count":75,"is_preprint":false},{"pmid":"1766675","id":"PMC_1766675","title":"erg, an ets-related gene, codes for sequence-specific transcriptional activators.","date":"1991","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/1766675","citation_count":75,"is_preprint":false},{"pmid":"35879310","id":"PMC_35879310","title":"Dysfunctional ERG signaling drives pulmonary vascular aging and persistent fibrosis.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35879310","citation_count":74,"is_preprint":false},{"pmid":"21321361","id":"PMC_21321361","title":"Promotion and maintenance of leukemia by ERG.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21321361","citation_count":72,"is_preprint":false},{"pmid":"28344039","id":"PMC_28344039","title":"Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.","date":"2017","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/28344039","citation_count":69,"is_preprint":false},{"pmid":"24762546","id":"PMC_24762546","title":"Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.","date":"2014","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/24762546","citation_count":63,"is_preprint":false},{"pmid":"30500808","id":"PMC_30500808","title":"Downregulation of ERG and FLI1 expression in endothelial cells triggers endothelial-to-mesenchymal transition.","date":"2018","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30500808","citation_count":62,"is_preprint":false},{"pmid":"15090257","id":"PMC_15090257","title":"Functions of erg K+ channels in excitable cells.","date":"2004","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15090257","citation_count":60,"is_preprint":false},{"pmid":"8076344","id":"PMC_8076344","title":"ERG gene is translocated in an Ewing's sarcoma cell line.","date":"1994","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/8076344","citation_count":59,"is_preprint":false},{"pmid":"28986382","id":"PMC_28986382","title":"Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28986382","citation_count":55,"is_preprint":false},{"pmid":"25263440","id":"PMC_25263440","title":"TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25263440","citation_count":52,"is_preprint":false},{"pmid":"23086769","id":"PMC_23086769","title":"Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.","date":"2012","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23086769","citation_count":52,"is_preprint":false},{"pmid":"21170267","id":"PMC_21170267","title":"ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.","date":"2010","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/21170267","citation_count":51,"is_preprint":false},{"pmid":"20636794","id":"PMC_20636794","title":"ERG rearrangement in small cell prostatic and lung cancer.","date":"2010","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/20636794","citation_count":49,"is_preprint":false},{"pmid":"23898196","id":"PMC_23898196","title":"Structural and dynamic studies of the transcription factor ERG reveal DNA binding is allosterically autoinhibited.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23898196","citation_count":47,"is_preprint":false},{"pmid":"27223260","id":"PMC_27223260","title":"BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27223260","citation_count":44,"is_preprint":false},{"pmid":"19151660","id":"PMC_19151660","title":"TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas.","date":"2009","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/19151660","citation_count":44,"is_preprint":false},{"pmid":"32541654","id":"PMC_32541654","title":"An Erg-driven transcriptional program controls B cell lymphopoiesis.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32541654","citation_count":43,"is_preprint":false},{"pmid":"32701507","id":"PMC_32701507","title":"ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming.","date":"2020","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/32701507","citation_count":42,"is_preprint":false},{"pmid":"33531470","id":"PMC_33531470","title":"Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33531470","citation_count":41,"is_preprint":false},{"pmid":"31749034","id":"PMC_31749034","title":"ISCEV extended protocol for the S-cone ERG.","date":"2019","source":"Documenta ophthalmologica. Advances in ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/31749034","citation_count":41,"is_preprint":false},{"pmid":"32871104","id":"PMC_32871104","title":"DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3β and WEE1.","date":"2020","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/32871104","citation_count":39,"is_preprint":false},{"pmid":"25378537","id":"PMC_25378537","title":"ERG expression in chondrogenic bone and soft tissue tumours.","date":"2014","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25378537","citation_count":38,"is_preprint":false},{"pmid":"28055969","id":"PMC_28055969","title":"TMPRSS2-ERG fusion promotes prostate cancer metastases in bone.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28055969","citation_count":38,"is_preprint":false},{"pmid":"28248553","id":"PMC_28248553","title":"Synergistic Role of Endothelial ERG and FLI1 in Mediating Pulmonary Vascular Homeostasis.","date":"2017","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28248553","citation_count":38,"is_preprint":false},{"pmid":"34230470","id":"PMC_34230470","title":"EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34230470","citation_count":37,"is_preprint":false},{"pmid":"17143509","id":"PMC_17143509","title":"ERG upregulation and related ETS transcription factors in prostate cancer.","date":"2007","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17143509","citation_count":37,"is_preprint":false},{"pmid":"36095844","id":"PMC_36095844","title":"EVI1 drives leukemogenesis through aberrant ERG activation.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/36095844","citation_count":36,"is_preprint":false},{"pmid":"27109047","id":"PMC_27109047","title":"ETS transcription factor ERG cooperates with histone demethylase KDM4A.","date":"2016","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/27109047","citation_count":35,"is_preprint":false},{"pmid":"11312105","id":"PMC_11312105","title":"Selective expression of erg isoforms in human endothelial cells.","date":"2001","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11312105","citation_count":34,"is_preprint":false},{"pmid":"29911685","id":"PMC_29911685","title":"Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers.","date":"2018","source":"European urology oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29911685","citation_count":33,"is_preprint":false},{"pmid":"30718921","id":"PMC_30718921","title":"TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30718921","citation_count":32,"is_preprint":false},{"pmid":"35563163","id":"PMC_35563163","title":"The Expression of Proto-Oncogene ETS-Related Gene (ERG) Plays a Central Role in the Oncogenic Mechanism Involved in the Development and Progression of Prostate Cancer.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35563163","citation_count":31,"is_preprint":false},{"pmid":"24504051","id":"PMC_24504051","title":"ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24504051","citation_count":31,"is_preprint":false},{"pmid":"27041928","id":"PMC_27041928","title":"PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer.","date":"2016","source":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","url":"https://pubmed.ncbi.nlm.nih.gov/27041928","citation_count":30,"is_preprint":false},{"pmid":"29202479","id":"PMC_29202479","title":"SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29202479","citation_count":28,"is_preprint":false},{"pmid":"22140532","id":"PMC_22140532","title":"ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22140532","citation_count":26,"is_preprint":false},{"pmid":"23472063","id":"PMC_23472063","title":"5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23472063","citation_count":25,"is_preprint":false},{"pmid":"23555854","id":"PMC_23555854","title":"ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23555854","citation_count":24,"is_preprint":false},{"pmid":"26653555","id":"PMC_26653555","title":"Elevated expression of microRNA-30b in osteoarthritis and its role in ERG regulation of chondrocyte.","date":"2015","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/26653555","citation_count":23,"is_preprint":false},{"pmid":"21731703","id":"PMC_21731703","title":"Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21731703","citation_count":23,"is_preprint":false},{"pmid":"21178489","id":"PMC_21178489","title":"ERG oncogene modulates prostaglandin signaling in prostate cancer cells.","date":"2011","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21178489","citation_count":23,"is_preprint":false},{"pmid":"30051493","id":"PMC_30051493","title":"Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.","date":"2018","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/30051493","citation_count":22,"is_preprint":false},{"pmid":"25972242","id":"PMC_25972242","title":"Expression of ERG protein in prostate cancer: variability and biological correlates.","date":"2015","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25972242","citation_count":22,"is_preprint":false},{"pmid":"23380710","id":"PMC_23380710","title":"AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL.","date":"2013","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/23380710","citation_count":21,"is_preprint":false},{"pmid":"20814243","id":"PMC_20814243","title":"The oncogenic role of the ETS transcription factors MEF and ERG.","date":"2010","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/20814243","citation_count":20,"is_preprint":false},{"pmid":"29167279","id":"PMC_29167279","title":"Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer.","date":"2017","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29167279","citation_count":20,"is_preprint":false},{"pmid":"23462600","id":"PMC_23462600","title":"Immunohistochemical evaluation of ERG expression in various benign and malignant tissues.","date":"2013","source":"Annals of clinical and laboratory science","url":"https://pubmed.ncbi.nlm.nih.gov/23462600","citation_count":20,"is_preprint":false},{"pmid":"36443337","id":"PMC_36443337","title":"Extensive germline-somatic interplay contributes to prostate cancer progression through HNF1B co-option of TMPRSS2-ERG.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36443337","citation_count":20,"is_preprint":false},{"pmid":"26061019","id":"PMC_26061019","title":"Endothelial Erg expression is required for embryogenesis and vascular integrity.","date":"2015","source":"Organogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/26061019","citation_count":19,"is_preprint":false},{"pmid":"31757416","id":"PMC_31757416","title":"ERG the modulates Warburg effect and tumor progression in cervical cancer.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31757416","citation_count":19,"is_preprint":false},{"pmid":"28436588","id":"PMC_28436588","title":"Reduced Erg Dosage Impairs Survival of Hematopoietic Stem and Progenitor Cells.","date":"2017","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/28436588","citation_count":19,"is_preprint":false},{"pmid":"23703293","id":"PMC_23703293","title":"ERG expression and prostatic adenocarcinoma.","date":"2013","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23703293","citation_count":18,"is_preprint":false},{"pmid":"32164354","id":"PMC_32164354","title":"High Specificity of BCL11B and GLG1 for EWSR1-FLI1 and EWSR1-ERG Positive Ewing Sarcoma.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32164354","citation_count":18,"is_preprint":false},{"pmid":"36088396","id":"PMC_36088396","title":"Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer.","date":"2022","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/36088396","citation_count":17,"is_preprint":false},{"pmid":"30150711","id":"PMC_30150711","title":"Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30150711","citation_count":17,"is_preprint":false},{"pmid":"34647226","id":"PMC_34647226","title":"LncRNA SNHG3 Facilitates the Malignant Phenotype of Cholangiocarcinoma Cells via the miR-3173-5p/ERG Axis.","date":"2021","source":"Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract","url":"https://pubmed.ncbi.nlm.nih.gov/34647226","citation_count":17,"is_preprint":false},{"pmid":"25139621","id":"PMC_25139621","title":"Erg cooperates with TGF-β to control mesenchymal differentiation.","date":"2014","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/25139621","citation_count":17,"is_preprint":false},{"pmid":"37181497","id":"PMC_37181497","title":"PCA3 and TMPRSS2: ERG Urine Level as Diagnostic Biomarker of Prostate Cancer.","date":"2023","source":"Research and reports in urology","url":"https://pubmed.ncbi.nlm.nih.gov/37181497","citation_count":16,"is_preprint":false},{"pmid":"29427188","id":"PMC_29427188","title":"Molecular characteristic of acute leukemias with t(16;21)/FUS-ERG.","date":"2018","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/29427188","citation_count":16,"is_preprint":false},{"pmid":"29225123","id":"PMC_29225123","title":"Clinical Utility and Biologic Implications of Phosphatase and Tensin Homolog (PTEN) and ETS-related Gene (ERG) in Prostate Cancer.","date":"2017","source":"Urology","url":"https://pubmed.ncbi.nlm.nih.gov/29225123","citation_count":16,"is_preprint":false},{"pmid":"35513774","id":"PMC_35513774","title":"Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer.","date":"2022","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35513774","citation_count":16,"is_preprint":false},{"pmid":"15988032","id":"PMC_15988032","title":"The oncogenic TLS-ERG fusion protein exerts different effects in hematopoietic cells and fibroblasts.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15988032","citation_count":16,"is_preprint":false},{"pmid":"26122367","id":"PMC_26122367","title":"ERG and FLI1 are useful immunohistochemical markers in phosphaturic mesenchymal tumors.","date":"2015","source":"Medical molecular morphology","url":"https://pubmed.ncbi.nlm.nih.gov/26122367","citation_count":16,"is_preprint":false},{"pmid":"26711283","id":"PMC_26711283","title":"ERG expression in prostate cancer: biological relevance and clinical implication.","date":"2015","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26711283","citation_count":15,"is_preprint":false},{"pmid":"34852650","id":"PMC_34852650","title":"Periodontitis Risk Variants at SIGLEC5 Impair ERG and MAFB Binding.","date":"2021","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/34852650","citation_count":15,"is_preprint":false},{"pmid":"32934023","id":"PMC_32934023","title":"ERG-Mediated Coregulator Complex Formation Maintains Androgen Receptor Signaling in Prostate Cancer.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32934023","citation_count":15,"is_preprint":false},{"pmid":"25344575","id":"PMC_25344575","title":"ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer.","date":"2014","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/25344575","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49273,"output_tokens":10841,"usd":0.155217,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21887,"output_tokens":6867,"usd":0.140555,"stage2_stop_reason":"end_turn"},"total_usd":0.295772,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1987,\n      \"finding\": \"ERG (erg gene) encodes a protein with ~40% and ~70% homology to the 5' and 3' domains of v-ets oncogene, respectively, establishing it as a member of the ETS oncogene family with a distinct transcript size from Hu-ets1 and Hu-ets2.\",\n      \"method\": \"cDNA cloning, nucleotide sequence analysis, Northern blot\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct sequencing and biochemical characterization of the founding paper, independently replicated across the field\",\n      \"pmids\": [\"3476934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"ERG-1 and ERG-2 proteins (produced by alternative splicing and alternative initiation codons) bind DNA in a sequence-specific manner and transactivate reporter genes linked to ERG target sequences, establishing ERG as a sequence-specific transcriptional activator with partially overlapping but distinct DNA-binding specificity compared to other ETS members.\",\n      \"method\": \"Recombinant protein expression in E. coli, DNA-binding assays, transactivation reporter assays in transient transfection\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro biochemical reconstitution with purified recombinant protein plus functional transcription assay, foundational paper replicated by subsequent studies\",\n      \"pmids\": [\"1766675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ERG gene on chromosome 21 is fused to the 5' end of EWS in Ewing's sarcoma, placing the ERG ETS DNA-binding domain adjacent to the EWS CTD-related region and generating an elevated EWS/ERG fusion transcript — the first reported structural alteration of ERG in human cancer.\",\n      \"method\": \"Cytogenetics, RT-PCR, transcript detection in cell line\",\n      \"journal\": \"Cancer genetics and cytogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — molecular characterization of the fusion in a cell line with RT-PCR validation, single lab\",\n      \"pmids\": [\"8076344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The TLS-ERG leukemia fusion protein binds RNA polymerase II through its TLS N-terminal domain but, unlike wild-type TLS, cannot recruit serine-arginine (SR) splicing factors because the ERG portion replaces the TLS C-terminal SR-recruiting domain; as a result, TLS-ERG inhibits SR-mediated E1A pre-mRNA splicing and alters CD44 mRNA splicing in stable K562 cells.\",\n      \"method\": \"Co-immunoprecipitation, transient transfection splicing assay, stable expression in K562 cells, RT-PCR of CD44 splice variants, deletion analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (Co-IP, in-cell splicing assay, stable expression), mechanistic dissection with deletion mutants\",\n      \"pmids\": [\"10779324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Among multiple ERG isoforms, Erg-3/p55(ERG) and p38(ERG)-like transcripts are selectively expressed in human endothelial cells (both microvascular and large vessel), suggesting isoform-specific roles in regulating endothelial-restricted genes.\",\n      \"method\": \"RT-PCR, Northern blotting, 5'-RACE on primary and established human endothelial cells\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct isoform characterization in freshly isolated and cultured ECs, multiple molecular methods, single lab\",\n      \"pmids\": [\"11312105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TLS-ERG binds RNA polymerase II via its first 173 amino acids; in myeloid L-G cells TLS-ERG represses glycoprotein IX promoter activity, while in NIH 3T3 fibroblasts it alters E1A splicing but not GpIX transcription — demonstrating cell-type-specific mechanisms of transformation through different gene sets.\",\n      \"method\": \"Deletion mutant analysis, luciferase reporter assays, splicing reporter assay, stable retroviral expression, microarray gene expression profiling in two cell lines\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — systematic deletion analysis, dual cell-line model, multiple orthogonal functional readouts\",\n      \"pmids\": [\"15988032\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ERG and its splice variant C-1-1 (hERG3Δ81) are expressed in developing mouse limb joints and overexpression of hERG3Δ81 throughout the cartilaginous skeleton of transgenic mice inhibits chondrocyte maturation/hypertrophy (absent growth plates, loss of Indian hedgehog, collagen X, MMP-13) while maintaining articular markers, placing ERG downstream of GDF-5 in joint formation.\",\n      \"method\": \"In vivo transgenic mouse model (Col2a1-driven overexpression), GDF-5 bead implantation in explants, immunostaining and marker expression analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo transgenic mouse with specific skeletal phenotype, GDF-5 induction experiment, replicated in two species (chick and mouse)\",\n      \"pmids\": [\"17336282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ERG binds the VE-cadherin promoter (shown by ChIP) and transactivates it; inhibition of ERG in HUVECs reduces VE-cadherin expression, disrupts cell-cell contacts, and increases apoptosis; overexpression of VE-cadherin rescues ERG-knockdown-induced apoptosis; in vivo ERG siRNA reduces Matrigel plug vascularization with increased caspase-positive ECs.\",\n      \"method\": \"Antisense oligonucleotide knockdown, siRNA, chromatin immunoprecipitation (ChIP), transactivation assay, VE-cadherin-GFP overexpression rescue, in vivo Matrigel plug model, caspase staining\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP establishing direct promoter binding, in vitro functional rescue, in vivo vascularization model, multiple orthogonal methods\",\n      \"pmids\": [\"18195090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TMPRSS2-ERG fusion product induces an invasion-associated transcriptional program in prostate epithelial cells and directly engages the plasminogen activation pathway to mediate cellular invasion; transgenic mice expressing ERG under androgen regulation develop prostatic intraepithelial neoplasia.\",\n      \"method\": \"Transgenic mouse model, stable overexpression in primary/immortalized prostate cells, ERG knockdown in VCaP cells, transcriptional profiling, invasion assays\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo transgenic model plus in vitro gain/loss-of-function with defined invasion phenotype and pathway identification, replicated across multiple model systems\",\n      \"pmids\": [\"18283340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Ectopic ERG expression in fetal hematopoietic progenitors promotes megakaryopoiesis and causes rapid-onset leukemia in mice; ERG cooperates strongly with the GATA1s mutant protein to immortalize megakaryocyte progenitors, and endogenous ERG is required for proliferation/maintenance of AMKL cell lines.\",\n      \"method\": \"Retroviral overexpression in fetal liver progenitors, in vivo mouse transplantation, shRNA knockdown of ERG in human AMKL lines, colony-forming assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo leukemia model plus human cell line loss-of-function, GATA1s cooperation established genetically, multiple labs have replicated the megakaryocytic oncogenic role\",\n      \"pmids\": [\"19487285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ETS2 and ERG overexpression immortalize Gata1-knockdown and Gata1s-knockin (but not wild-type) murine fetal liver megakaryocyte progenitors in serial replating; immortalization is accompanied by activation of the JAK/STAT pathway.\",\n      \"method\": \"Retroviral overexpression in Gata1 mutant fetal liver progenitors, serial replating assay, flow cytometry (CD41/CD42), JAK/STAT signaling analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with Gata1 mutants, functional immortalization assay, pathway identification, independent confirmation of ERG-GATA1s cooperation\",\n      \"pmids\": [\"19168790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ERG forced expression in adult bone marrow cells promotes T-cell and erythroid expansion and increases myeloid progenitor frequency; T cells develop T-ALL after acquiring Notch1 mutations; ERG targeted to B cells promotes precursor-B-cell growth; shRNA silencing of ERG attenuates growth of human leukemia lines of multiple lineages.\",\n      \"method\": \"Retroviral overexpression and shRNA knockdown in mouse BM transplantation models; B-cell targeted expression; human leukemia cell line knockdown\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo BM transplantation model plus human cell line KD, multi-lineage phenotypic characterization, independent of prior megakaryocyte work\",\n      \"pmids\": [\"21321361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TMPRSS2-ERG directly binds the TFF3 promoter ETS sites (by ChIP and ChIP-seq), inhibiting TFF3 expression in hormone-naive cancer but not in castration-resistant prostate cancer; AR signaling modulates ERG-regulated TFF3 expression; TFF3 overexpression enhances ERG-mediated invasion in CRPC cells.\",\n      \"method\": \"ChIP-PCR and ChIP-seq in VCaP cells and tissue specimens, transcriptome profiling of 54 CRPC samples, invasion assays with TFF3 overexpression\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct ChIP/ChIP-seq establishing promoter binding, validated in human tissue, functional invasion assay, multiple orthogonal methods\",\n      \"pmids\": [\"21170267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ERG directly binds the PIM1 promoter (by ChIP) in prostate cells and upregulates PIM1 expression; all three ERG oncogenic fusions (TMPRSS2/ERG, EWS/ERG, FUS/ERG) upregulate PIM1 in NIH-3T3; tERG-induced PIM1 upregulation increases Cyclin B1 levels and aneuploidy after taxane treatment.\",\n      \"method\": \"Chromatin immunoprecipitation, stable expression of ERG fusions in NIH-3T3 and RWPE-1, siRNA knockdown, gene expression microarray, flow cytometry\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating direct promoter binding, consistent across three fusion types, single lab\",\n      \"pmids\": [\"22140532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ERG-mediated regulation of SOX9 is indirect: ERG redirects AR to a cryptic AR-regulated enhancer in the SOX9 gene, thereby driving androgen-stimulated SOX9 expression; SOX9 depletion in VCaP cells impairs invasion and growth in vitro and in vivo, establishing SOX9 as a critical downstream effector of ERG.\",\n      \"method\": \"RNAi knockdown in VCaP cells, ChIP-seq to map ERG/AR binding at SOX9 enhancer, SOX9 shRNA knockdown, in vivo xenograft, correlation in 3 independent cohorts\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP-seq-defined mechanism, in vitro and in vivo functional validation, 3 independent clinical cohorts, multiple orthogonal methods\",\n      \"pmids\": [\"23426182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ERG DNA binding is allosterically autoinhibited by flanking regions outside the ETS domain. Crystal structures of uninhibited, autoinhibited, and DNA-bound ERG were solved; NMR backbone dynamics show that uninhibited ERG exhibits millisecond-to-microsecond dynamics that are quenched in autoinhibited and DNA-bound states, revealing that autoinhibition is predominantly mediated by regulation of Ets-domain dynamics rather than large structural changes.\",\n      \"method\": \"X-ray crystallography (three crystal structures), NMR backbone dynamics measurements, functional DNA-binding assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures plus NMR dynamics plus functional assay, multiple orthogonal biophysical methods in single rigorous study\",\n      \"pmids\": [\"23898196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ERG governs loss of DNA methylation at the TDRD1 promoter CpG island, leading to TDRD1 transcriptional activation in TMPRSS2:ERG-positive prostate cancer; this was demonstrated by ERG dosage manipulation (siRNA and forced expression) and MeDIP-seq/bisulfite sequencing showing inverse correlation between ERG and TDRD1 promoter methylation.\",\n      \"method\": \"siRNA knockdown and forced expression of ERG, MeDIP-Seq and bisulfite sequencing, DNMT inhibitor treatment, quantitative RT-PCR, clinical specimen analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MeDIP-seq and bisulfite sequencing with direct ERG dosage manipulation, single lab\",\n      \"pmids\": [\"23555854\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ERG is recruited to the ANXA2 promoter (shown by ChIP) and transcriptionally represses ANXA2; ERG knockdown enhances apical ANXA2 localization and promotes polarized epithelial phenotype; ERG overexpression disrupts ANXA2-mediated cell polarity and promotes EMT by inhibiting CDC42 and RHOA and activating cofilin.\",\n      \"method\": \"ChIP, siRNA knockdown, ERG overexpression, immunofluorescence of ANXA2 localization, RHOA/CDC42/cofilin activity assays, IHC in clinical specimens\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP-based direct promoter binding, gain/loss-of-function with defined signaling readouts, clinical specimen validation\",\n      \"pmids\": [\"25344575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ERG overexpression in CRPC cells affects microtubule dynamics and inhibits effective drug-target engagement of docetaxel or cabazitaxel with tubulin, suggesting ERG functions outside the nucleus to confer taxane resistance.\",\n      \"method\": \"ERG overexpression in in vitro and in vivo CRPC models, microtubule dynamics assays, drug-target engagement assays, clinical cohort analysis (34 patients)\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic microtubule assay plus in vivo model, single lab, novel non-nuclear function proposed with functional data\",\n      \"pmids\": [\"25420520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ERG cooperates with TGF-β signaling: ERG expression is induced by TGF-β in sclerotome cells; Erg and Smad3 co-immunoprecipitate, indicating direct protein-protein interaction; ERG overexpression inhibits hyaline cartilage differentiation (reduced Alcian blue, Sox9, c-Maf) and upregulates Sca1; TGF-β enhances ERG-mediated differentiation marker expression.\",\n      \"method\": \"Micromass culture, adenoviral ERG overexpression, co-immunoprecipitation (Erg/Smad3), TGF-β bead implantation in chick embryo, Alcian blue staining, qRT-PCR\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP establishing Erg/Smad3 interaction, in vitro and in vivo functional assays, single lab\",\n      \"pmids\": [\"25139621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SPOP (Cullin 3-based E3 ubiquitin ligase adaptor) promotes ubiquitination and proteasomal degradation of ERG by recognizing a degron motif at the ERG N-terminus; truncated TMPRSS2-ERG fusion proteins lacking the N-terminal degron are resistant to SPOP-mediated degradation; prostate cancer-associated SPOP mutants are deficient in promoting ERG ubiquitination; CKI-mediated phosphorylation modulates the SPOP/ERG interaction; DNA damage drugs can restore SPOP/ΔERG interaction and degradation via CKI activation.\",\n      \"method\": \"Ubiquitination assay, co-immunoprecipitation, proteasome inhibitor treatment, SPOP mutant expression, CKI activation by DNA damage drugs, in vitro and in vivo experiments\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — biochemical ubiquitination assay, degron mapping, phosphorylation modulation, replicated in companion paper (PMID 26344096), two independent labs\",\n      \"pmids\": [\"26344095\", \"26344096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ERG activates the YAP1 transcriptional program: ERG binds chromatin regions co-occupied by TEAD/YAP1 and transactivates Hippo target genes; in human luminal prostate cancer cells, ERG binds the YAP1 promoter and is necessary for YAP1 expression; prostate-specific activation of ERG or YAP1 in mice induces similar transcriptional changes and age-related prostate tumors.\",\n      \"method\": \"ChIP-seq (ERG/TEAD/YAP1 binding), ERG and YAP1 promoter ChIP, mouse genetic models (prostate-specific ERG or YAP1 activation), transcriptional profiling\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP-seq genome-wide binding, in vivo genetic evidence of shared transcriptional program, direct promoter binding established\",\n      \"pmids\": [\"26058078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ERG directly promotes YAP1 expression by binding to multiple sites within the human YAP1 gene promoter, cooperating with histone demethylase KDM4A (JMJD2A) which removes H3K9me3 at the YAP1 promoter; ERG and KDM4A physically interact (co-IP); YAP1 depletion phenocopies ERG or KDM4A depletion in VCaP cells.\",\n      \"method\": \"Co-immunoprecipitation (ERG-KDM4A), ChIP (H3K9me3 at YAP1 promoter), luciferase promoter assays with ERG-binding-site mutations, siRNA knockdown, growth assays\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP, ChIP, mutational promoter analysis, single lab\",\n      \"pmids\": [\"27109047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ERG drives genome-wide retargeting of BAF (mammalian SWI/SNF) ATP-dependent chromatin remodeling complexes in a manner dependent on ERG binding to ETS DNA motifs; ERG requires intact BAF complexes for chromatin occupancy and BAF ATPase activity for target gene regulation; ERG interacts with BAF complexes (shown by binding interaction experiments); BAF complexes are required for ERG-mediated basal-to-luminal transition in prostate organoids.\",\n      \"method\": \"Co-immunoprecipitation/binding interaction experiments, ChIP-seq (ERG and BAF), BAF ATPase inhibition, prostate organoid model with BAF complex perturbation\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genome-wide ChIP-seq demonstrating ERG-dependent BAF retargeting, biochemical interaction, mechanistic dissection with organoid model, multiple orthogonal methods\",\n      \"pmids\": [\"30078722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Combined knockdown of ERG and FLI1 in endothelial cells induces EndMT coupled with dynamic epigenetic changes; ERG (and FLI1) are critical transcriptional activators of EC-specific genes; microRNA-126, a target of ERG/FLI1, partially contributes to blocking EndMT; ERG and FLI1 expression is downregulated in ECs within tumors by soluble factors from the tumor microenvironment.\",\n      \"method\": \"siRNA knockdown (ERG, FLI1, combined), genome-wide ChIP-seq and ATAC-seq, EndMT phenotyping, miR-126 rescue experiments, conditioned medium experiments\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genome-wide chromatin and expression analysis plus functional EndMT assay, miR-126 rescue, multiple orthogonal methods\",\n      \"pmids\": [\"30500808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The TMPRSS2-ERG truncated fusion protein (ERGΔ39/T1-E4) binds bromodomain-1 (BD1) of BRD4; this interaction is partially abrogated by BET inhibitors JQ1 and iBET762; ChIP-seq shows substantial overlap of ERG and BRD4 binding sites; an acetylation-mimicking ERG mutation augments the ERG-BRD4 interaction and enhances ERG-mediated invasion.\",\n      \"method\": \"Co-immunoprecipitation (ERG-BRD4), BET inhibitor treatment, ChIP-seq meta-analysis, acetylation-mimicking mutation, invasion assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and ChIP-seq with functional mutation, single lab, one method per key claim\",\n      \"pmids\": [\"27223260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Deregulation of DUX4 in B-progenitor ALL initiates transcription of a novel ERG isoform (ERGalt) from a non-canonical first exon via DUX4 binding; ERGalt retains the DNA-binding and transactivation domains of ERG but acts as a dominant-negative inhibitor of wild-type ERG transcriptional activity and is transforming.\",\n      \"method\": \"RNA-seq, genomic rearrangement analysis, functional transactivation assays (dominant-negative), transformation assays, DUX4 binding site characterization\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — discovery of novel isoform with molecular mechanism defined (DUX4 binding, dominant-negative activity), functional transformation assays, large cohort study\",\n      \"pmids\": [\"27776115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Peptides and derived peptidomimetics (ERG inhibitory peptides, EIPs) interact specifically with the DNA-binding domain of ERG; binding leads to proteolytic degradation of ERG protein; EIPs attenuate ERG-mediated transcription, chromatin recruitment, protein-protein interactions, cell invasion and proliferation, and tumor growth in vivo.\",\n      \"method\": \"Peptide binding assays, protease degradation assay, ERG ChIP after EIP treatment, transcriptional reporter assays, invasion/proliferation assays, xenograft tumor model\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — biochemical binding to specific domain, multiple functional readouts including in vivo, mechanistic degradation mechanism identified\",\n      \"pmids\": [\"28344039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FOXO1 (but not FOXO3 or FOXO4) directly binds ERG and inhibits its transcriptional activity independently of FOXO1's own transcriptional activity; FOXO1 knockdown increases invasion of VCaP cells in an ERG-dependent manner; combined ERG overexpression and homozygous Foxo1 deletion in mouse prostate cooperates to produce high-grade PIN, while either alone does not.\",\n      \"method\": \"Co-immunoprecipitation (FOXO1-ERG), transcriptional reporter assay, siRNA knockdown, mouse genetic model (ERG transgene + Foxo1 deletion), cell invasion assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP establishing direct interaction, genetic epistasis in mouse model, biochemical activity assay, multiple orthogonal methods\",\n      \"pmids\": [\"28986382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ERG directly and specifically regulates expression of the α1 and β1 subunits of soluble guanylyl cyclase (sGC) in prostate cancer cells; ERG-driven sGC expression increases cGMP synthesis and PKG activity, promoting cell proliferation; sGC inhibitor treatment represses TMPRSS2-ERG-positive tumor growth in xenograft models and synergizes with enzalutamide.\",\n      \"method\": \"ERG knockdown/overexpression in PCa cells, ChIP (ERG at sGC subunit loci), cGMP measurement, PKG activity assay, xenograft tumor model, pharmacological inhibition\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP-defined direct regulation, biochemical pathway readout (cGMP/PKG), in vivo xenograft, multiple orthogonal methods\",\n      \"pmids\": [\"30718921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"DNA damage induces proteasomal degradation of ERG and TMPRSS2-ERG oncoprotein through dual phosphorylation at threonine-187 (by GSK3β) and tyrosine-190 (by WEE1); this dual phosphorylation triggers recognition and degradation by the E3 ubiquitin ligase FBW7 independent of a canonical degron; DNA-damage-induced TMPRSS2-ERG degradation is abolished by PTEN deletion or GSK3β inactivation.\",\n      \"method\": \"In vitro phosphorylation assays, ubiquitination assays, mutagenesis (T187 and Y190), FBW7 Co-IP and degradation assays, GSK3β/WEE1 inhibition, PTEN deletion models, xenograft chemotherapy experiments\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assays, site-directed mutagenesis, biochemical ubiquitination reconstitution, in vivo validation, mechanistic dissection of novel PTM-driven degradation pathway\",\n      \"pmids\": [\"32871104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ERG initiates a transcriptional network in early B lymphoid differentiation, directly promoting expression of B-cell lineage-defining genes Ebf1 and Pax5, which in turn regulate key genes for V(D)J recombination and B-cell receptor formation; ERG deficiency in B-cell development is rescued by a productively rearranged immunoglobulin gene, placing ERG as an essential stage-specific regulator upstream of V(D)J recombination.\",\n      \"method\": \"Erg conditional knockout, transcriptional profiling, ChIP-seq, Ig gene rescue complementation experiment, flow cytometric characterization of B-cell progenitor stages\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic rescue experiment establishing epistasis, ChIP-seq identifying direct targets, conditional KO with precise developmental phenotype\",\n      \"pmids\": [\"32541654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ERG orchestrates 3D chromatin interactions in prostate cancer to enforce luminal cell identity: ERG binds and inhibits the enhancer activity and chromatin looping of a Trp63 distal enhancer, silencing Trp63 expression and suppressing basal lineage differentiation; specific deletion of the ERG-bound distal enhancer element abolishes ERG-mediated inhibition of basal differentiation.\",\n      \"method\": \"Integration of transcription factor analysis across 806 human PCa transcriptomes, 3D chromatin architecture analysis (Hi-C/chromatin conformation), ChIP-seq, CRISPR enhancer deletion, ERG/AR conditional KO in organoids\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genome-wide chromatin architecture, CRISPR enhancer deletion establishing causality, conditional KO epistasis, multiple orthogonal methods\",\n      \"pmids\": [\"32701507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In established prostate cancer organoids, ERG deletion does not drastically alter AR binding, H3K27ac enhancer, or open chromatin profiles at ERG-reprogrammed sites, but does cause loss of critical AR coregulators (NCOA3) and RNA polymerase II from AR-bound sites, revealing that ERG maintains AR signaling by sustaining coregulator complexes rather than by controlling AR binding.\",\n      \"method\": \"Murine prostate organoids (Pten KO + ERG OE), ERG deletion in established organoids, ChIP-seq (AR, H3K27ac), ATAC-seq, proteomic analysis of DNA-bound AR complexes\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — proteomics of AR complexes, ChIP-seq and ATAC-seq genome-wide, organoid genetic model, multiple orthogonal methods\",\n      \"pmids\": [\"32934023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EZH2 methylates ERG at lysine K362 within the internal autoinhibitory domain; K362 methylation modifies intradomain interactions, favors DNA binding, and enhances ERG transcriptional activity; in PTEN-null prostate cancer, AKT activation leads to EZH2 phosphorylation at serine 21, promoting ERG methylation; ERG and EZH2 physically interact and co-occupy genomic sites forming trans-activating complexes.\",\n      \"method\": \"In vitro methylation assay, site-directed mutagenesis (K362), Co-IP (ERG-EZH2), ChIP-seq, genetically engineered mouse model (ERG/PTEN), AKT/EZH2 signaling dissection\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro methylation reconstitution with mutagenesis, structural domain mechanistic dissection, in vivo mouse model, ChIP-seq co-occupancy, multiple orthogonal methods\",\n      \"pmids\": [\"34230470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ERG upregulates wild-type SPOP to dampen AR signaling and sustains its own activity through SPOP-mediated degradation of the bromodomain histone reader ZMYND11; conversely, SPOP-mutant tumors stabilize ZMYND11 which represses ERG function, creating a synthetic-sick interaction between ERG and SPOP mutation; ERG promotes sensitivity to high-dose androgen therapy and pharmacological SPOP inhibition.\",\n      \"method\": \"ERG/SPOP gain and loss of function, ZMYND11 protein stability assays, AR signaling readouts, pharmacological inhibition, clinical cohort analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic dissection of ERG-SPOP-ZMYND11-AR axis, pharmacological and genetic perturbation, clinical validation, multiple orthogonal methods\",\n      \"pmids\": [\"33531470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ERG knockdown in endothelial cells (HUVECs) promotes secretion of endothelin-1 (ET-1), which in a paracrine manner accelerates proliferation, phenotypic transition, and collagen synthesis of cardiac fibroblasts; suppressing ET-1 (neutralizing antibody or receptor blocker) abolishes ERG-knockdown-mediated pro-fibrotic effects; endothelial ERG overexpression prevents pressure-overload-induced cardiac fibrosis in vivo.\",\n      \"method\": \"siRNA knockdown of ERG in HUVECs, ET-1 ELISA, cardiac fibroblast co-culture/conditioned medium, ET-1 neutralizing antibody/receptor blocker, RGD-peptide nanoparticle siRNA delivery in vivo, pressure-overload mouse model with ERG overexpression\",\n      \"journal\": \"Cell biology and toxicology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — paracrine mechanism identified with ET-1 rescue, in vivo mouse model, pharmacological and genetic interventions, multiple orthogonal methods\",\n      \"pmids\": [\"33469864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EVI1 oncogene directly transcriptionally activates ERG by occupying a conserved intragenic enhancer region; ERG is a direct transcriptional target of EVI1 and is selectively required in EVI1-driven AML; ERG suppression induces terminal differentiation of EVI1-driven AML cells; ectopic ERG expression abrogates EVI1 dependence, placing ERG downstream of EVI1 as the major oncogenic effector.\",\n      \"method\": \"EVI1 withdrawal experiments, genome-wide CRISPR screens for dependencies, ChIP-seq (EVI1 at ERG enhancer), ERG shRNA knockdown, ERG ectopic expression rescue, differentiation assays in human and murine AML models\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP-seq direct enhancer binding, CRISPR genetic dependency, genetic rescue epistasis, validated in human and murine models\",\n      \"pmids\": [\"36095844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Loss of endothelial ERG in young mice impairs lung fibrosis resolution; ERG dysregulation in aged lungs is associated with reduced chromatin accessibility at ERG target loci and maladaptive transcriptional responses to injury; ERG deficiency enhances paracrine fibroblast activation in vitro; scRNA-seq of ERG-deficient mouse lungs shows transcriptional and fibrogenic abnormalities resembling aging, including reduced general capillary (gCap) ECs.\",\n      \"method\": \"Conditional endothelial ERG KO, bleomycin fibrosis model, ATAC-seq (epigenetic chromatin accessibility), scRNA-seq, in vitro paracrine fibroblast activation assay, young vs. aged mouse comparison\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — conditional KO with in vivo fibrosis model, ATAC-seq, scRNA-seq, in vitro mechanistic assay, multiple orthogonal methods\",\n      \"pmids\": [\"35879310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HNF1B interacts with TMPRSS2-ERG to co-occupy large genomic regions enriched for PCa risk alleles; the HNF1B eQTL signal is ERG fusion-status dependent, indicating that ERG mediates the transcriptional effects of the 17q12/HNF1B risk locus; HNF1B co-opts ERG fusion to mediate the biological effects of the 17p13.3 PCa risk locus.\",\n      \"method\": \"Co-expression analysis, eQTL analysis stratified by ERG status, ChIP-seq co-occupancy analysis, functional pathway analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq co-occupancy and eQTL conditional on ERG status, single study, predominantly genomic/computational with functional validation\",\n      \"pmids\": [\"36443337\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ERG is an ETS-family transcription factor that binds DNA sequence-specifically (with autoinhibition mediated by flanking domains regulating Ets-domain dynamics), transactivates or represses target genes (including VE-cadherin, SOX9, YAP1, sGC subunits, TFF3, PIM1, ANXA2, FZD8, TDRD1, and Trp63 enhancer), physically interacts with AR, BAF chromatin remodeling complexes, BRD4, EZH2 (which methylates ERG at K362 to enhance DNA binding), FOXO1 (which inhibits ERG), Smad3, and RNA polymerase II; its protein stability is regulated by SPOP/CRL3-mediated ubiquitin-proteasomal degradation (targeting an N-terminal degron, modulated by CKI and by GSK3β/WEE1-dependent dual phosphorylation that recruits FBW7); in the vasculature ERG is essential for endothelial survival, angiogenesis, and homeostasis, partly through direct transactivation of VE-cadherin and suppression of ET-1 secretion; in hematopoiesis ERG drives megakaryopoiesis, maintains hematopoietic stem cells, and is the key downstream effector of EVI1-driven AML; in prostate cancer the TMPRSS2-ERG fusion redirects AR to cryptic enhancers (e.g., SOX9), retargets BAF complexes genome-wide, maintains coregulator (NCOA3) recruitment to AR-bound sites, orchestrates chromatin looping to suppress basal lineage differentiation, and is regulated by EZH2 methylation and SPOP/FBW7 degradation pathways; in the TLS-ERG leukemia fusion, the ERG portion displaces TLS C-terminal SR splicing-factor recruitment, causing aberrant RNA splicing and cell-type-specific transcriptional reprogramming.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ERG is an ETS-family sequence-specific transcription factor that orchestrates lineage-defining transcriptional programs in vascular endothelium, hematopoiesis, and skeletal development, and is co-opted as a dominant oncogenic driver when structurally rearranged [#0, #1, #8]. Its DNA-binding ETS domain is allosterically autoinhibited by flanking regions that quench Ets-domain conformational dynamics, a regulatory switch relieved by EZH2-mediated methylation of K362 within the internal autoinhibitory domain to favor DNA binding and transactivation [#15, #34]. In the vasculature ERG directly transactivates VE-cadherin to maintain endothelial cell-cell junctions and survival, supports angiogenesis, and represses endothelin-1 secretion, thereby restraining paracrine fibroblast activation and cardiac/lung fibrosis; combined loss with FLI1 drives endothelial-to-mesenchymal transition [#7, #36, #24, #38]. In hematopoiesis ERG drives megakaryopoiesis, cooperates with the GATA1s mutant to immortalize progenitors, supports B-lymphoid differentiation upstream of Ebf1/Pax5 and V(D)J recombination, and is the principal transcriptional effector of EVI1-driven AML [#9, #10, #31, #37]. When fused (TMPRSS2-ERG, EWS-ERG, FUS/TLS-ERG), ERG reprograms transcription: it retargets BAF/SWI-SNF chromatin remodeling complexes genome-wide, redirects AR to cryptic enhancers and sustains AR coregulator (NCOA3) and Pol II occupancy, orchestrates 3D chromatin looping to silence the Trp63 enhancer and suppress basal differentiation, and directly activates or represses targets including SOX9, YAP1 (with KDM4A), the sGC \\u03b11/\\u03b21 subunits, TFF3, PIM1, ANXA2, and TDRD1 to promote invasion and proliferation [#23, #33, #32, #14, #21, #29]. The TLS-ERG fusion instead acts through RNA Pol II binding while failing to recruit SR splicing factors, causing aberrant, cell-type-specific RNA splicing [#3, #5]. ERG protein abundance is tightly controlled by ubiquitin-proteasomal degradation through the SPOP/CRL3 adaptor recognizing an N-terminal degron and through GSK3\\u03b2/WEE1 dual phosphorylation (T187/Y190) that recruits FBW7, pathways exploited by truncated fusions that escape degron-dependent turnover [#20, #30].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Establishing the molecular identity of ERG answered whether it was a distinct gene, defining it as a member of the ETS oncogene family separate from ets1/ets2.\",\n      \"evidence\": \"cDNA cloning, sequencing, and Northern blot\",\n      \"pmids\": [\"3476934\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define DNA-binding specificity or transcriptional function\", \"No cellular role assigned\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Showing ERG isoforms bind DNA sequence-specifically and transactivate reporters established ERG as a bona fide transcription factor rather than merely an ETS-homologous ORF.\",\n      \"evidence\": \"Recombinant protein DNA-binding and transactivation reporter assays\",\n      \"pmids\": [\"1766675\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological target genes unknown\", \"Tissue context undefined\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Identifying EWS-ERG fusion in Ewing's sarcoma revealed that ERG's ETS domain becomes oncogenic through structural fusion, the first cancer alteration of ERG.\",\n      \"evidence\": \"Cytogenetics and RT-PCR in a cell line\",\n      \"pmids\": [\"8076344\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell line, no mechanistic dissection of fusion activity\", \"Target genes of fusion not defined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Dissecting the TLS-ERG fusion answered how it transforms, revealing that the ERG portion displaces TLS SR splicing-factor recruitment to cause aberrant splicing while retaining Pol II binding.\",\n      \"evidence\": \"Co-IP, in-cell splicing assays, deletion analysis in K562 cells\",\n      \"pmids\": [\"10779324\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo leukemogenesis not shown\", \"Full set of mis-spliced transcripts unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Comparing TLS-ERG effects across cell lines established that its transcriptional/splicing consequences are cell-type-specific, mapping Pol II binding to the N-terminal 173 residues.\",\n      \"evidence\": \"Deletion mutants, reporter and splicing assays, microarrays in two cell lines\",\n      \"pmids\": [\"15988032\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of cell-type specificity not identified\", \"Primary patient relevance untested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identifying VE-cadherin as a direct ERG target answered how ERG maintains the endothelium, linking ERG to junctional integrity, survival, and angiogenesis.\",\n      \"evidence\": \"ChIP, knockdown/rescue, in vivo Matrigel plug, caspase staining\",\n      \"pmids\": [\"18195090\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full endothelial target network not mapped\", \"Upstream regulators of ERG in EC unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Linking TMPRSS2-ERG to an invasion program and PIN in transgenic mice established ERG fusion as a driver of prostate oncogenesis via the plasminogen activation pathway.\",\n      \"evidence\": \"Transgenic mice, gain/loss-of-function in prostate cells, invasion assays\",\n      \"pmids\": [\"18283340\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct chromatin targets not yet defined\", \"Cooperating lesions for full transformation unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Multiple studies established ERG as a broad hematopoietic oncogene, driving megakaryopoiesis, cooperating with GATA1s, and supporting multi-lineage leukemias.\",\n      \"evidence\": \"Retroviral overexpression/shRNA in mouse BM transplants and human leukemia lines, serial replating, JAK/STAT analysis\",\n      \"pmids\": [\"19487285\", \"19168790\", \"21321361\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets in each lineage incompletely defined\", \"Mechanism of GATA1s cooperation at chromatin unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Solving ERG crystal structures with NMR dynamics answered how DNA binding is regulated, showing autoinhibition operates by quenching Ets-domain dynamics rather than gross conformational change.\",\n      \"evidence\": \"Three X-ray structures, NMR backbone dynamics, DNA-binding assays\",\n      \"pmids\": [\"23898196\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How post-translational modifications alter these dynamics not addressed here\", \"Partner-protein influence on autoinhibition unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Mapping ERG-regulated targets in prostate cancer (SOX9, TFF3, PIM1, TDRD1, ANXA2) revealed both direct ETS-site binding and AR-redirection, establishing the effector genes for invasion and EMT.\",\n      \"evidence\": \"ChIP/ChIP-seq, MeDIP-seq, knockdown/overexpression, xenografts, clinical cohorts\",\n      \"pmids\": [\"23426182\", \"21170267\", \"22140532\", \"23555854\", \"25344575\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of each target to tumorigenesis unranked\", \"Direct vs. AR-mediated mechanism varies by target\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identifying a non-nuclear ERG effect on microtubule dynamics proposed a mechanism for taxane resistance distinct from its transcriptional role.\",\n      \"evidence\": \"Overexpression, microtubule and drug-target engagement assays, clinical cohort\",\n      \"pmids\": [\"25420520\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ERG-tubulin interaction not biochemically defined\", \"Single lab, mechanism of cytoplasmic localization unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrating ERG-Smad3 interaction and TGF-\\u03b2 induction of ERG connected ERG to TGF-\\u03b2 signaling in skeletal differentiation.\",\n      \"evidence\": \"Micromass culture, Co-IP, TGF-\\u03b2 bead implantation in chick, marker analysis\",\n      \"pmids\": [\"25139621\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Co-IP not reciprocally validated for endogenous proteins\", \"Direct target genes of ERG-Smad3 complex undefined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identifying SPOP/CRL3 as the E3 ligase recognizing an N-terminal ERG degron answered how ERG protein is degraded and why truncated fusions escape turnover.\",\n      \"evidence\": \"Ubiquitination assays, degron mapping, SPOP-mutant and CKI/DNA-damage modulation, in vivo\",\n      \"pmids\": [\"26344095\", \"26344096\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay with other degradation pathways not yet integrated\", \"CKI site on ERG not precisely mapped here\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Establishing the ERG-YAP1/Hippo axis (with KDM4A cooperation) revealed a transcriptional program shared with YAP1 that drives prostate tumorigenesis.\",\n      \"evidence\": \"ChIP-seq, promoter ChIP/luciferase, Co-IP, mouse genetic models\",\n      \"pmids\": [\"26058078\", \"27109047\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether YAP1 fully accounts for ERG tumor phenotype unresolved\", \"KDM4A-ERG interaction from single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defining ERG's recruitment of BAF remodelers and interaction with BRD4 answered how fusion ERG reorganizes chromatin to reprogram lineage identity.\",\n      \"evidence\": \"Co-IP/binding, ChIP-seq, BAF ATPase inhibition, organoids, BET inhibitor and acetylation-mimic experiments\",\n      \"pmids\": [\"30078722\", \"27223260\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and direct interface of ERG-BAF binding undefined\", \"BRD4 interaction characterized in single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Discovering EndMT control by ERG/FLI1 and ERGalt dominant-negative isoform expanded ERG's roles to endothelial identity maintenance and a novel B-ALL transforming mechanism.\",\n      \"evidence\": \"siRNA knockdown, ChIP-seq/ATAC-seq, miR-126 rescue, RNA-seq, transactivation/transformation assays\",\n      \"pmids\": [\"30500808\", \"27776115\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of ERGalt across B-ALL subtypes incompletely defined\", \"Tumor-microenvironment factors downregulating ERG unidentified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"ERG inhibitory peptides binding the DNA-binding domain established druggability and confirmed that disrupting ERG-DNA/protein interactions degrades ERG and blocks tumor growth.\",\n      \"evidence\": \"Peptide binding, protease degradation assay, ChIP, reporter and invasion assays, xenografts\",\n      \"pmids\": [\"28344039\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degradation mechanism downstream of peptide binding not fully detailed\", \"Clinical translation untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identifying FOXO1 as a direct ERG-binding inhibitor revealed an endogenous brake on ERG transcriptional activity that cooperates genetically in PIN.\",\n      \"evidence\": \"Co-IP, reporter assays, knockdown, mouse ERG transgene + Foxo1 deletion, invasion\",\n      \"pmids\": [\"28986382\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of FOXO1-ERG inhibition undefined\", \"Whether FOXO1 affects ERG at all target loci unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Linking ERG to direct activation of sGC \\u03b11/\\u03b21 subunits revealed a cGMP/PKG proliferative pathway and a druggable vulnerability synergizing with enzalutamide.\",\n      \"evidence\": \"ChIP, knockdown/overexpression, cGMP/PKG assays, xenografts, pharmacological inhibition\",\n      \"pmids\": [\"30718921\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether sGC axis operates in non-prostate ERG contexts untested\", \"Upstream signals converging on this pathway unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Three studies clarified how fusion ERG maintains AR signaling and lineage identity: it sustains AR coregulators/Pol II rather than AR binding, and enforces luminal identity by silencing a Trp63 enhancer through 3D looping; ERG also governs B-lineage transcription.\",\n      \"evidence\": \"Organoid ERG deletion, AR/H3K27ac ChIP-seq, ATAC-seq, proteomics, Hi-C, CRISPR enhancer deletion, conditional KO, Ig rescue\",\n      \"pmids\": [\"32701507\", \"32934023\", \"32541654\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which ERG retains NCOA3/Pol II at AR sites undefined\", \"Generalizability of looping mechanism to other ERG targets unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defining GSK3\\u03b2/WEE1 dual phosphorylation (T187/Y190) recruiting FBW7 revealed a degron-independent, DNA-damage-inducible route to ERG degradation gated by PTEN status.\",\n      \"evidence\": \"Kinase and ubiquitination assays, mutagenesis, FBW7 Co-IP, PTEN deletion, xenograft chemotherapy\",\n      \"pmids\": [\"32871104\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crosstalk with SPOP/CKI degron pathway not fully integrated\", \"Whether this operates in non-prostate ERG tumors untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"EZH2 methylation of ERG-K362 and the ERG-SPOP-ZMYND11 feedback loop answered how ERG activity and stability are reciprocally tuned, linking PTEN/AKT signaling and SPOP-mutation status to ERG function.\",\n      \"evidence\": \"In vitro methylation, mutagenesis, Co-IP, ChIP-seq, ERG/PTEN mouse model, ZMYND11 stability and clinical analyses\",\n      \"pmids\": [\"34230470\", \"33531470\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative impact of K362 methylation on genome-wide binding incompletely mapped\", \"Therapeutic exploitation of SPOP-ERG synthetic-sick interaction unproven clinically\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Establishing ERG as the direct EVI1 transcriptional effector and the HNF1B partnership clarified ERG's place in AML dependency and prostate cancer risk-locus biology.\",\n      \"evidence\": \"EVI1 withdrawal, CRISPR screens, ChIP-seq, shRNA/ectopic rescue, eQTL stratified by ERG status\",\n      \"pmids\": [\"36095844\", \"36443337\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"HNF1B finding predominantly genomic, single study\", \"Direct ERG-HNF1B physical interaction not biochemically confirmed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Endothelial ERG was shown to govern fibrosis resolution and aging-associated chromatin accessibility, extending its homeostatic role to tissue repair.\",\n      \"evidence\": \"Conditional endothelial KO, bleomycin model, ATAC-seq, scRNA-seq, paracrine assays\",\n      \"pmids\": [\"35879310\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ERG targets driving fibrosis resolution not pinpointed\", \"Mechanism of age-related ERG dysregulation unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the multiple ERG-regulatory layers — autoinhibition, K362 methylation, dual degron/phosphodegron degradation pathways, and partner complexes — are integrated to set context-specific ERG output across endothelium, hematopoiesis, and tumors remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unified model coordinating ERG PTMs, stability, and chromatin partners\", \"Determinants of cell-type-specific target selection undefined\", \"Translation of ERG-targeting strategies to clinic untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 7, 8, 14, 21, 29, 31, 37]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 15, 27]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [3, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 7, 23, 32]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 7, 8, 14, 21, 29]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [23, 24, 32, 34]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 8, 26, 37]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [20, 30, 35]}\n    ],\n    \"complexes\": [\"BAF (mammalian SWI/SNF)\"],\n    \"partners\": [\"AR\", \"BRD4\", \"EZH2\", \"FOXO1\", \"SMAD3\", \"KDM4A\", \"SPOP\", \"FBW7\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}